

CITATION REPORT

List of articles citing

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)

DOI: 10.1016/j.jinorgbio.2006.02.013

Journal of Inorganic Biochemistry, 2006, 100, 891-904.

Source: <https://exaly.com/paper-pdf/40542113/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
844	Dinuclear double-stranded metallocsupramolecular ruthenium complexes: potential anticancer drugs. 2006 , 45, 4839-42		96
843	Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy. 2006 , 2006, 4003-4018		518
842	Dinuclear Double-Stranded Metallocsupramolecular Ruthenium Complexes: Potential Anticancer Drugs. 2006 , 118, 4957-4960		38
841	Contributions of DNA interstrand cross-links to aging of cells and organisms. 2007 , 35, 7566-76		71
840	Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. 2007 , 22, 960-967		81
839	Ruthenium complexes can target determinants of tumour malignancy. <i>Dalton Transactions</i> , 2007 , 1267-723		238
838	Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin. 2007 , 46, 9048-50		107
837	Binding of antitumor ruthenium complexes to DNA and proteins: a theoretical approach. 2007 , 111, 9955-64		33
836	Metal based drugs: from serendipity to design. <i>Dalton Transactions</i> , 2007 , 4903-17	4.3	301
835	¹⁰⁶ Ru radiolabelling of the antitumour complex [(eta ⁶ -fluorene)Ru(en)Cl]PF ₆ . <i>Dalton Transactions</i> , 2007 , 4974-9	4.3	15
834	Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. <i>Dalton Transactions</i> , 2007 , 5065-72	4.3	119
833	Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties. 2007 , 46, 5023-33		55
832	The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro. 2007 , 46, 3645-56		36
831	Half-sandwich Ru(II)-[9]aneS ₃ complexes with dicarboxylate ligands: synthesis, characterization and chemical behavior. <i>Dalton Transactions</i> , 2007 , 4048-58	4.3	24
830	Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl ₄ L(S-dmsu)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity. 2007 , 50, 2185-93		191
829	Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. 2007 , 79, 2243-2261		243
828	Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5-methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound. 2007 , 50, 5871-4		48

827	Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. 2007 , 50, 6343-55	80
826	Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines. 2007 , 46, 4374-8	167
825	Non platinum metal complexes as anti-cancer drugs. 2007 , 340, 117-26	424
824	Dinuclear Ruthenium(II) Triple-Stranded Helicates: Luminescent Supramolecular Cylinders That Bind and Coil DNA and Exhibit Activity against Cancer Cell Lines. 2007 , 119, 4452-4456	56
823	Synthesis of Cycloruthenated Compounds as Potential Anticancer Agents. 2007 , 2007, 3055-3066	67
822	Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE. 2007 , 28, 2235-40	45
821	CE in anticancer metallodrug research--an update. 2007 , 28, 3436-46	58
820	ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes. 2007 , 2, 631-5	85
819	Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis. 2007 , 1155, 218-21	31
818	Synthesis, characterization, X-ray structure and preliminary in vitro antitumor activity of the nitrosyl complex fac-[RuCl ₃ (NO)(dppf)], dppf=1,1'-bis(diphenylphosphine)ferrocene. 2007 , 26, 4707-4712	46
817	Synthesis and characterization of ionic Ru(III) complexes containing dimethylsulfoxide and dinitrogen heterocyclic ligands. 2007 , 26, 3661-3668	23
816	Synthesis and structural characterization of cobalt(II) and zinc(II) complexes with 2-(indazol-1-yl)-2-thiazoline (TnInA). X-ray characterization of [CoCl ₂ (TnInA) ₂][C ₂ H ₆ O] and [(M)(TnInA) ₂ (H ₂ O) ₂](NO ₃) ₂ (M=Co, Zn). 2007 , 26, 5210-5218	9
815	Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. 2007 , 21, 1521-30	19
814	Understanding the chemical mechanisms of life. 2007 , 3, 745-9	1
813	Analysis in vivo of antitumor activity, cytotoxicity and Interaction between plasmid DNA and the cis-dichloro-tetra-amine-ruthenium(III) chloride. 2007 , 167, 116-24	27
812	Remarkable Anticancer Activity of Triruthenium-Arene Clusters Compared to Tetraruthenium-Arene Clusters. 2007 , 18, 741-752	48
811	Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c. 2007 , 12, 1107-17	46
810	Synthesis, structural characteristics, DNA binding properties and cytotoxicity studies of a series of Ru(III) complexes. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1644-53	4.2 185

809	Cytotoxic and DNA-binding properties of two ruthenium(II) porphyrin complexes. 2008 , 33, 1053-1058	5
808	Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. 2008 , 13, 511-20	32
807	The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. 2008 , 13, 1149-55	210
806	The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. 2008 , 27, 67-100	74
805	In vitro anticancer activity and biologically relevant metabolism of organometallic ruthenium complexes with carbohydrate-based ligands. 2008 , 14, 9046-57	100
804	Cellular uptake, cytotoxicity, and metabolic profiling of human cancer cells treated with ruthenium(II) polypyridyl complexes [Ru(bpy) ₂ (N-N)]Cl ₂ with N-N=bpy, phen, dpq, dppz, and dppn. 2008 , 3, 1104-9	232
803	Osmium carbonyl clusters: a new class of apoptosis inducing agents. 2008 , 3, 1269-75	39
802	Influence of the Diketonato Ligand on the Cytotoxicities of [Ru(1,5-cymene)(R ₂ acac)(PTA)] ⁺ Complexes (PTA = 1,3,5-triaza-7-phosphaadamantane). 2008 , 2008, 1661-1671	80
801	Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma. 2008 , 29, 2224-32	82
800	Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication. 2008 , 5, 1609-14	32
799	Phosphite-derivatized ruthenium-carbohydrate complexes in the catalytic hydration of nitriles. short communication. 2008 , 5, 1640-4	22
798	The hydration of chloroacetonitriles catalyzed by mono- and dinuclear Ru(II)- and Os(II)-arene complexes. 2008 , 5, 2060-6	21
797	KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. 2008 , 5, 2140-55	624
796	The "complex-in-a-complex" cations [(acac) ₂ M subset Ru ₆ (p-iPrC ₆ H ₄ Me) ₆ (tpt) ₂ (dhbq) ₃] ⁶⁺ : A trojan horse for cancer cells. 2008 , 47, 3773-6	381
795	Modifying the structure of dinuclear ruthenium complexes with antitumor activity. 2008 , 22, 326-332	45
794	The "Complex-in-a-Complex" Cations [(acac) ₂ M subset Ru ₆ (p-iPrC ₆ H ₄ Me) ₆ (tpt) ₂ (dhbq) ₃] ⁶⁺ : A Trojan Horse for Cancer Cells. 2008 , 120, 3833-3836	105
793	Diruthenium(II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: Synthesis, characterization and their effects on tumor-cell proliferation. 2008 , 27, 1131-1137	79
792	Water-soluble arene ruthenium complexes containing pyridinethiolato ligands: Synthesis, molecular structure, redox properties and anticancer activity of the cations [(1,5-arene)Ru(p-SC ₅ H ₄ NH) ₃] ²⁺ . 2008 , 693, 3419-3424	22

791	Differences in structure, physiological stability, electrochemistry, cytotoxicity, DNA and protein binding properties between two Ru(III) complexes. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 347-58	4.2	133
790	Influence of the anionic ligands on the anticancer activity of Ru(II)-dmsO complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 606-17	4.2	17
789	Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1066-76	4.2	95
788	Cyclic tetranuclear half-sandwich ruthenium(II) complexes with 4,7-phenanthroline and hydroxo bridges: crystal structure, solution behaviour and binding to nucleosides. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1025-32	4.2	8
787	CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1060-5	4.2	87
786	Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1120-33	4.2	41
785	Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta ⁶ -p-cymene)Cl ₂ (pta)]. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1743-8	4.2	95
784	Synthesis, characterization, X-ray structure and in vitro antimycobacterial and antitumoral activities of Ru(II) phosphine/diimine complexes containing the "SpymMe ₂ " ligand, SpymMe ₂ =4,6-dimethyl-2-mercaptopyrimidine. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1783-9	4.2	46
783	[RuII(NO ⁺)] ₃ ⁺ -core complexes with 4-methyl-pyrimidine and ethyl-isonicotinate: synthesis, X-ray structure, spectroscopy, and computational and NO-release studies upon UVA irradiation. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1874-84	4.2	5
782	Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 2136-41	4.2	57
781	Toward high-throughput monitoring of metallodrug-protein interaction using capillary electrophoresis in chemically modified capillaries. 2008 , 379, 216-8		17
780	Electron-transfer activated metal-based anticancer drugs. 2008 , 361, 1569-1583		168
779	Mononuclear arene ruthenium complexes containing 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-triazine as chelating ligand: Synthesis and molecular structure. 2008 , 361, 2601-2608		18
778	Analyzing Ru(III)dmso and Ru(III)dms motifs in compounds used in the synthesis of the antimetastatic agents. 2008 , 891, 64-74		8
777	Ruthenium porphyrin compounds for photodynamic therapy of cancer. 2008 , 51, 1811-6		210
776	An electrochemical study of antineoplastic gallium, iron and ruthenium complexes with redox noninnocent alpha-N-heterocyclic chalcogensemicarbazones. 2008 , 47, 11032-47		51
775	Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity. 2008 , 47, 578-83		124
774	Antitumour metal compounds: more than theme and variations. <i>Dalton Transactions</i> , 2008 , 183-94	4.3	702

773	Aquation of the ruthenium-based anticancer drug NAMI-A: a density functional study. 2008 , 112, 3871-5		33
772	Mixed ligand ruthenium(II) complexes of bis(pyrid-2-yl)-/bis(benzimidazol-2-yl)-dithioether and diimines: study of non-covalent DNA binding and cytotoxicity. <i>Dalton Transactions</i> , 2008 , 148-63	4-3	110
771	Computational Electrochemistry of Ruthenium Anticancer Agents. Unprecedented Benchmarking of Implicit Solvation Methods. 2008 , 4, 499-506		29
770	Mechanism of cellular uptake of a ruthenium polypyridyl complex. 2008 , 47, 11711-6		274
769	Water-Soluble Mixed-Ligand Ruthenium(II) and Osmium(II) Arene Complexes with High Antiproliferative Activity. 2008 , 27, 6587-6595		64
768	Resistance against novel anticancer metal compounds: differences and similarities. 2008 , 11, 1-16		183
767	Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl ₄ (indazole) ₂]-. 2008 , 47, 6513-23		48
766	Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. 2008 , 47, 17-9		87
765	Non-covalent DNA binding and cytotoxicity of certain mixed-ligand ruthenium(II) complexes of 2,2'-dipyridylamine and diimines. <i>Dalton Transactions</i> , 2008 , 2157-70	4-3	132
764	Synthesis and cytotoxicity of dinuclear complexes containing ruthenium(II) bipyridyl units linked by a bis(pyridylimine) ligand. <i>Dalton Transactions</i> , 2008 , 667-75	4-3	39
763	Synthesis, structure, spectroscopic properties, and antiproliferative activity in vitro of novel osmium(III) complexes withazole heterocycles. 2008 , 47, 7338-47		27
762	Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex. 2008 , 47, 274-80		40
761	Importance of the Ligand: Remarkable Effect of the Cyclopentadienyl Ring on the Cytotoxicity of Ruthenium PTA Compounds. 2008 , 27, 1355-1357		49
760	Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium-Arene Compounds. 2008 , 27, 2405-2407		171
759	Ruthenium(III) chloride complex with a tridentate bis(arylimino)pyridine ligand: synthesis, spectra, X-ray structure, 9-ethylguanine binding pattern, and in vitro cytotoxicity. 2008 , 47, 6964-73		27
758	Alkyne hexacarbonyl dicobalt complexes in medicinal chemistry and drug development. 2008 , 18, 327-337		27
757	. 2009 ,		101
756	Kinetic and Mechanistic Studies on the Reaction of DL-Methionine with in Aqueous Medium at Physiological pH. 2009 , 2009, 1-5		1

755	Ruthenium, Titanium and Gallium for Treating Cancer. 149-189		
754	New platinum and ruthenium complexes--the latest class of potential chemotherapeutic drugs--a review of recent developments in the field. 2009 , 9, 1489-503		34
753	The rational design of anticancer platinum complexes: the importance of the structure-activity relationship. <i>Current Medicinal Chemistry</i> , 2009 , 16, 2235-60	4-3	108
752	Organometallic compounds in oncology: implications of novel organotins as antitumor agents. 2009 , 14, 500-8		189
751	Role of cell cycle events and apoptosis in mediating the anti-cancer activity of a silver(I) complex of 4-hydroxy-3-nitro-coumarin-bis(phenanthroline) in human malignant cancer cells. 2009 , 602, 203-14		53
750	Rational Design of an Organometallic Glutathione Transferase Inhibitor. 2009 , 121, 3912-3915		20
749	Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro. 2009 , 15, 12283-91		102
748	A cytotoxic ruthenium tris(bipyridyl) complex that accumulates at plasma membranes. 2009 , 10, 1796-800		77
747	Cycloruthenated Compounds [Synthesis and Applications. 2009 , 2009, 817-853		197
746	New Insights into the Chemistry of the Antineoplastic Lanthanum Complex Tris(1,10-phenanthroline)tris(thiocyanato- κ)lanthanum(III) (KP772) and Its Interaction with Biomolecules. 2009 , 2009, 4282-4287		30
745	[Tris(pyrazolyl)methane]ruthenium Complexes Capable of Inhibiting Cancer Cell Growth. 2009 , 2009, 4629-4633		12
744	The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques. 2009 , 30, 2720-7		43
743	Rational design of an organometallic glutathione transferase inhibitor. 2009 , 48, 3854-7		159
742	A novel cytotoxic cerium complex: aquatrchloridobis(1,10-phenanthroline)cerium(III) (KP776). Synthesis, characterization, behavior in H ₂ O, binding towards biomolecules, and antiproliferative activity. 2009 , 6, 2153-65		12
741	Ruthenium polypyridyl complexes and their modes of interaction with DNA: is there a correlation between these interactions and the antitumor activity of the compounds?. 2009 , 14, 439-48		70
740	Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. 2009 , 14, 761-70		88
739	Electronic structural investigations of ruthenium compounds and anticancer prodrugs. 2009 , 14, 891-8		20
738	Mutagenic and genotoxic effects of cis-(dichloro)tetraammineruthenium(III) chloride on human peripheral blood lymphocytes. 2009 , 130, 249-61		13

737	Inhibition of cancer cell growth by ruthenium(II) cyclopentadienyl derivative complexes with heteroaromatic ligands. <i>Journal of Inorganic Biochemistry</i> , 2009 , 103, 354-61	4.2	65
736	Preliminary chemico-biological studies on Ru(III) compounds with S-methyl pyrrolidine/dimethyl dithiocarbamate. <i>Journal of Inorganic Biochemistry</i> , 2009 , 103, 774-82	4.2	17
735	Induction of apoptosis by hexaosmium carbonyl clusters. 2009 , 694, 834-839		22
734	Arene-ruthenium complexes with ferrocene-derived ligands: Synthesis and characterization of complexes of the type $[\text{Ru}(\eta\text{-arene})(\text{NC}_5\text{H}_4\text{CH}_2\text{NHOC-C}_5\text{H}_4\text{FeC}_5\text{H}_5)\text{Cl}_2]$ and $[\text{Ru}(\eta\text{-arene})(\text{NC}_3\text{H}_3\text{N}(\text{CH}_2)_2\text{O}_2\text{C}\eta\text{-C}_5\text{H}_4\text{FeC}_5\text{H}_5)\text{Cl}_2]$. 2009 , 694, 855-861		53
733	Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. 2009 , 694, 922-929		58
732	Organometallic complexes that interconvert between trimeric and monomeric structures as a function of pH and their effect on human cancer and fibroblast cells. 2009 , 694, 968-972		31
731	Anticancer activity of multinuclear arene ruthenium complexes coordinated to dendritic polypyridyl scaffolds. 2009 , 694, 3470-3476		89
730	Synthesis of new heterometallic macromolecules: their DNA binding, cleavage activity and in vitro model electrochemotherapy study. 2009 , 74, 1152-9		6
729	Functionalised $\eta\text{-arene}$ ruthenium complexes. <i>Coordination Chemistry Reviews</i> , 2009 , 253, 493-519	23.2	176
728	Sawhorse-type diruthenium tetracarbonyl complexes. <i>Coordination Chemistry Reviews</i> , 2009 , 253, 2639-2664	23.2	47
727	Organometallic ruthenium complexes with thiosemicarbazone ligands: Synthesis, structure and cytotoxicity of $[(\eta\text{-p-cymene})\text{Ru}(\text{NS})\text{Cl}]$ (NS = 9-anthraldehyde thiosemicarbazones). 2009 , 12, 1094-1098		63
726	Bioorganometallic chemistry--from teaching paradigms to medicinal applications. 2009 , 38, 391-401		840
725	Synthesis, structural characterisation and solution chemistry of ruthenium(III) triazole-thiadiazine complexes. <i>Dalton Transactions</i> , 2009 , 3766-73	4.3	9
724	Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta. 2009 , 28, 1165-1172		73
723	$[\text{Os}(\text{IV})\text{Cl}(\text{5})(\text{Hazole})](-)$ complexes: synthesis, structure, spectroscopic properties, and antiproliferative activity. 2009 , 48, 10737-47		20
722	Tuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium's success?. 2009 , 1, 541-59		16
721	Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. 2009 , 52, 916-25		156
720	Unusual DNA binding modes for metal anticancer complexes. 2009 , 91, 1198-211		173

719	Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity. <i>Dalton Transactions</i> , 2009 , 10742-56	4-3	53
718	From Pyrone to Thiopyrone Ligands Rendering Maltol-Derived Ruthenium(II) Arene Complexes That Are Anticancer Active in Vitro. 2009 , 28, 4249-4251		78
717	From cisplatin to photoreactive Ru complexes: targeting DNA for biomedical applications. <i>New Journal of Chemistry</i> , 2009 , 33, 235-245	3.6	84
716	Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic Compounds. 2009 , 28, 6260-6265		90
715	Microwave synthesis of mixed ligand diimine-thiosemicarbazone complexes of ruthenium(II): biophysical reactivity and cytotoxicity. <i>Dalton Transactions</i> , 2009 , 10757-64	4-3	75
714	Recent developments in ruthenium anticancer drugs. <i>Metallomics</i> , 2009 , 1, 458-70	4-5	492
713	Metals in Medicine: Therapeutic Agents. 2009 , 1		2
712	Ruthenium Drugs for Cancer Chemotherapy: An Ongoing Challenge to Treat Solid Tumours. 2009 , 57-66		6
711	Binding of organometallic ruthenium(II) anticancer compounds to nucleobases: a computational study. 2009 , 113, 11888-97		32
710	Molecular, Clinical and Environmental Toxicology. 2009 ,		10
709	Dual anti-angiogenic and cytotoxic properties of ruthenium(III) complexes containing pyrazolato and/or pyrazole ligands. <i>Dalton Transactions</i> , 2009 , 10712-6	4-3	31
708	Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. 2009 ,		15
707	Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design. <i>Advances in Inorganic Chemistry</i> , 2009 , 61, 1-62	2.1	162
706	A novel ruthenium(II) arene based intercalator with potent anticancer activity. <i>Dalton Transactions</i> , 2009 , 5071-3	4-3	29
705	Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents. <i>Dalton Transactions</i> , 2009 , 10914-25	4-3	44
704	A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity. <i>Dalton Transactions</i> , 2009 , 10727-30	4-3	9
703	Addition of ethynylferrocene to transition-metal complexes containing a chelating 1,2-dicarba-closo-dodecaborane-1,2-dichalcogenolate ligand--in vitro cooperativity of a ruthenium compound on cellular uptake of an anticancer drug. <i>Dalton Transactions</i> , 2009 , 285-90	4-3	40
702	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. 2009 , 24, 51-61		88

701	Novel and emerging approaches for the delivery of metallo-drugs. <i>Dalton Transactions</i> , 2009 , 10702-11	4-3	75
700	Synthesis, Molecular Structure, and Anticancer Activity of Cationic Arene Ruthenium Metallarectangles. 2009 , 28, 4350-4357		111
699	Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. 2009 , 20, 97-103		193
698	Novel metals and metal complexes as platforms for cancer therapy. 2010 , 16, 1813-25		327
697	Potential therapeutic applications of metal compounds directed towards hypoxic tissues. <i>Current Medicinal Chemistry</i> , 2010 , 17, 3616-31	4-3	12
696	Osmium(II)-versus ruthenium(II)-arene carbohydrate-based anticancer compounds: similarities and differences. <i>Dalton Transactions</i> , 2010 , 39, 7345-52	4-3	81
695	EXAFS, DFT, Light-Induced Nucleobase Binding, and Cytotoxicity of the Photoactive Complex cis-[Ru(bpy)2(CO)Cl]+. 2010 , 29, 6703-6710		36
694	Ruthenium-based chemotherapeutics: are they ready for prime time?. 2010 , 66, 1-9		358
693	Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR. 2010 , 15, 131-45		64
692	Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. 2010 , 15, 737-48		133
691	Metabolization of [Ru(eta(6)-C(6)H(5)CF(3))(pta)Cl(2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand. 2010 , 15, 919-27		43
690	The ruthenium complex cis-(dichloro)tetraammineruthenium(III) chloride presents selective cytotoxicity against murine B cell lymphoma (A-20), murine ascitic sarcoma 180 (S-180), human breast adenocarcinoma (SK-BR-3), and human T cell leukemia (Jurkat) tumor cell lines. 2010 , 135, 98-111		17
689	The ruthenium complex cis-(dichloro)tetraammineruthenium(III) chloride induces apoptosis and damages DNA in murine sarcoma 180 cells. 2010 , 35, 371-8		15
688	2-(3,5-Dibromo-4-hydroxyphenyl)imidazo[4,5-f][1,10]phenanthroline ruthenium(II) complexes: synthesis, characterization, cytotoxicity, apoptosis, DNA-binding and antioxidant activity. 2010 , 23, 739-52		24
687	Kinetic and mechanistic studies on the reaction of thiosemicarbazide with [(H2O)(tap)2RuORu(tap)2(H2O)]2+ {tap = 2-(m-tolylazo)pyridine}. 2010 , 35, 885-890		1
686	Evaluation of a Schiff base copper complex compound as potent anticancer molecule with multiple targets of action. 2010 , 647, 1-12		82
685	Redox-induced binding of [(tacn)Re(II)Br(CO)2]+ to guanine, oligonucleotides, and peptides. 2010 , 16, 2710-3		4
684	Evidence for drug release from a metalla-cage delivery vector following cellular internalisation. 2010 , 16, 1428-31		120

683	In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C. 2010 , 7, 1290-302		27
682	Trans-cis-cis-[RuCl ₂ (DMSO) ₂ (2-amino-5-methyl-thiazole) ₂], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. <i>Journal of Inorganic Biochemistry</i> , 2010 , 104, 111-74-2		16
681	In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. <i>Journal of Inorganic Biochemistry</i> , 2010 , 104, 79-86	4.2	147
680	Synthesis, characterization and cytotoxic activities of the [RuCl ₂ (NO)(dppp)(L)]PF ₆ complexes. <i>Journal of Inorganic Biochemistry</i> , 2010 , 104, 489-95	4.2	24
679	Mannich products of kojic acid and N-heterocycles and their Ru(II)-arene complexes: Synthesis, characterization and stability. 2010 , 695, 875-881		24
678	Binding to DNA purine bases and amino acid residues of a ruthenium(II) antitumor complex: A density functional study. 2010 , 363, 3274-3281		3
677	Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(1,5-cymene)(PPh ₂ (o-C ₆ H ₄ O)-2-P,O)(pta)] ⁺ and an investigation of its cytotoxic effects. 2010 , 13, 1144-1150		12
676	Synthesis, characterization and DNA binding studies of new ruthenium(II)bisterpyridine complexes. <i>European Journal of Medicinal Chemistry</i> , 2010 , 45, 284-91	6.8	78
675	Studies of the Antiproliferative Activity of Ruthenium (II) Cyclopentadienyl-Derived Complexes with Nitrogen Coordinated Ligands. 2010 ,		33
674	Organometallic Antitumour Agents with Alternative Modes of Action. 2010 , 57-80		55
673	DNA binding, cytotoxicity, and apoptotic-inducing activity of ruthenium(II) polypyridyl complex. 2010 , 42, 440-9		29
672	Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine. 2010 , 183097		2
671	Reaction of the Anticancer Organometallic Ruthenium Compound, [(eta-p-Cymene)Ru(ATSC)Cl]PF ₆ with Human Serum Albumin. 2010 , 2010, 1-7		18
670	Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy. 2010 , 10, 312-23		39
669	Recent insights on the medicinal chemistry of metal-based compounds: hints for the successful drug design. <i>Current Medicinal Chemistry</i> , 2010 , 17, 3739-50	4.3	19
668	Transport of therapeutic vanadium and ruthenium complexes by blood plasma components. <i>Current Medicinal Chemistry</i> , 2010 , 17, 3701-38	4.3	167
667	Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?. 2010 , 49, 7953-63		98
666	First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA. 2010 , 49, 10750-2		95

665	Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage. <i>Dalton Transactions</i> , 2010 , 39, 8248-55	4-3	76
664	Microwave-Assisted Selective Synthesis of 2H-Indazoles via Double Sonogashira Coupling of 3,4-Diiodopyrazoles and Bergman-Masamune Cycloaromatization. 2010 , 81, 1651		21
663	Use of perfluorinated phosphines to provide thermomorphic anticancer complexes for heat-based tumor targeting. 2010 , 49, 2239-46		34
662	Organometallic osmium arene complexes with potent cancer cell cytotoxicity. 2010 , 53, 8192-6		104
661	Antitumor activity of new hydridotris(pyrazolyl)borate ruthenium(II) complexes containing the phosphanes PTA and 1-CH ₃ -PTA. <i>Dalton Transactions</i> , 2010 , 39, 10186-96	4-3	22
660	Protease-activatable organometal-Peptide bioconjugates with enhanced cytotoxicity on cancer cells. 2010 , 21, 1288-96		59
659	The compound cis-(dichloro)tetrammineruthenium(III) chloride induces caspase-mediated apoptosis in K562 cells. 2010 , 24, 1562-8		13
658	Organometallic complexes: new tools for chemotherapy. <i>Current Medicinal Chemistry</i> , 2010 , 17, 2729-45	4-3	75
657	Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT. <i>Dalton Transactions</i> , 2010 , 39, 5556-63	4-3	74
656	Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity. 2010 , 53, 4678-90		112
655	Anticancer activity of opened arene ruthenium metalla-assemblies. <i>Dalton Transactions</i> , 2010 , 39, 5272-7	4-3	73
654	Synthesis, single-crystal and solution structure analysis and in vitro cytotoxic activity of two novel complexes of ruthenium(II) with in situ formed flavanone-based ligands. <i>Dalton Transactions</i> , 2010 , 39, 9711-8	4-3	17
653	Activation Mechanisms for Organometallic Anticancer Complexes. 2010 , 21-56		156
652	Medicinal Organometallic Chemistry. 2010 ,		66
651	In vitro cytotoxicity, apoptosis, DNA-binding, and antioxidant activity studies of ruthenium (II) complexes. 2010 , 29, 261-70		23
650	Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties. 2010 , 53, 6923-33		84
649	Cysteine proteases as targets for metal-based drugs. <i>Metallomics</i> , 2010 , 2, 366-77	4-5	108
648	Interactions between DNA purines and ruthenium ammine complexes within nanostructured sol-gel silica matrixes. 2010 , 114, 3987-98		4

647	Exploring the cellular accumulation of metal complexes. <i>Dalton Transactions</i> , 2010 , 39, 1159-70	4-3	194
646	Antiproliferative activity of chelating N,O- and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds. <i>Dalton Transactions</i> , 2011 , 40, 1158-67	4-3	140
645	Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. <i>Metallomics</i> , 2011 , 3, 591-9	4-5	106
644	Osmium(VI) complexes as a new class of potential anti-cancer agents. 2011 , 47, 2140-2		37
643	Mechanisms controlling the cellular accumulation of copper bis(thiosemicarbazonato) complexes. 2011 , 50, 9594-605		66
642	Water-soluble Cp ruthenium complex containing 1,3,5-triaza-7-phosphaadamantane and 8-thiotheophylline derivatives: synthesis, characterization, and antiproliferative activity. 2011 , 50, 873-82		29
641	Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents. 2011 , 47, 5184-6		120
640	Acetal-Functionalized RAPTA Complexes for Conjugation and Labeling. 2011 , 30, 5965-5971		27
639	Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin. <i>Dalton Transactions</i> , 2011 , 40, 1322-31	4-3	67
638	Physicochemical Studies and Anticancer Potency of Ruthenium η^5 -Cymene Complexes Containing Antibacterial Quinolones. 2011 , 30, 2506-2512		101
637	Ruthenium(II) complexes: structure, DNA-binding, photocleavage, antioxidant activity, and theoretical studies. 2011 , 64, 3792-3807		17
636	Ruthenium and Other Non-Platinum Anticancer Compounds. 2011 , 151-174		39
635	Poly(alkylidenamines) dendrimers as scaffolds for the preparation of low-generation ruthenium based metallodendrimers. <i>New Journal of Chemistry</i> , 2011 , 35, 1938	3.6	18
634	Interaction of <i>rac</i> -[M(diimine) ₃] ²⁺ (M=Co, Ni) complexes with CT DNA: role of 5,6-dmp ligand on DNA binding and cleavage and cytotoxicity. <i>Dalton Transactions</i> , 2011 , 40, 3245-56	4-3	78
633	LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma. <i>Metallomics</i> , 2011 , 3, 1049-55	4-5	58
632	Medicinal Inorganic Chemistry: State of the Art, New Trends, and a Vision of the Future. 2011 , 1-47		17
631	The Challenge of Establishing Reliable Screening Tests for Selecting Anticancer Metal Compounds. 2011 , 175-196		
630	Anticancer activity of metal complexes: involvement of redox processes. 2011 , 15, 1085-127		352

629	Application of ferrocene and its derivatives in cancer research. <i>New Journal of Chemistry</i> , 2011 , 35, 1973-6	3.6	358
628	1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity. <i>Dalton Transactions</i> , 2011 , 40, 5188-99	4.3	71
627	Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand. 2011 , 8, 949-57		36
626	. 2011 ,		115
625	A V-shaped ligand 1,3-bis(1-methylbenzimidazol-2-yl)-2-oxapropane and its Cu(II) complex: synthesis, crystal structure, antioxidation and DNA-binding properties. 2011 , 105, 190-7		20
624	Interaction of a "nido"-ruthenium terpyridylamine complex with charged elongated micellar scaffolds. 2011 , 88, 641-7		3
623	Ruthenium(II) phosphine/diimine/picolinate complexes: inorganic compounds as agents against tuberculosis. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 5099-107	6.8	62
622	Encapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage. 2011 , 6, 1595-603		57
621	Organometallic anticancer compounds. 2011 , 54, 3-25		1253
620	Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. <i>Dalton Transactions</i> , 2011 , 40, 7817-23	4.3	340
619	A QM/MM study of the binding of RAPTA ligands to cathepsin B. 2011 , 25, 729-42		34
618	Antileukemic activity and cellular effects of rhodium(III) crown thiaether complexes. 2011 , 24, 645-61		10
617	Thermal degradation behavior of some ruthenium complexes with fluoroquinolone derivatives as potential antitumor agents. 2011 , 105, 645-650		11
616	A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis. 2011 , 16, 715-24		36
615	Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. 2011 , 16, 1205-15		20
614	Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 1555-63	6.8	44
613	Ruthenium Porphyrin Complexes Induce Apoptosis by Inhibiting the Generation of Intracellular Reactive Oxygen Species in the Human Hepatoma Cell Line (HepG2). 2011 , 2011, 1974-1980		13
612	Polypyridyl Metal Complexes with Biological Activity. 2011 , 2011, 4931-4947		66

611	Synthesis and in vitro anticancer activity of ruthenium-cymene complexes with cyclohexyl-functionalized ethylenediamine-N,N'-diacetate-type ligands. 2011 , 6, 1884-91		18
610	Mono- and dinuclear (η^6 -arene) ruthenium(II) benzaldehyde thiosemicarbazone complexes: Synthesis, characterization and cytotoxicity. 2011 , 14, 956-960		50
609	Adding diversity to ruthenium(II) η^6 -arene anticancer (RAPTA) compounds via click chemistry: The influence of hydrophobic chains. 2011 , 696, 772-779		40
608	Organometallic ruthenium-based antitumor compounds with novel modes of action. 2011 , 696, 989-998		293
607	Pyrone derivatives and metals: From natural products to metal-based drugs. 2011 , 696, 999-1010		77
606	Cellular uptake, cytotoxicity, apoptosis, antioxidant activity and DNA binding of polypyridyl ruthenium(II) complexes. 2011 , 696, 2728-2735		34
605	DNA interaction and cytotoxicity studies of new ruthenium(II) cyclopentadienyl derivative complexes containing heteroaromatic ligands. <i>Journal of Inorganic Biochemistry</i> , 2011 , 105, 241-9	4.2	74
604	Recent progress in the application of analytical techniques to anticancer metallodrug proteomics. 2011 , 30, 1120-1138		42
603	Anticancer metallotherapeutics in preclinical development. <i>Current Medicinal Chemistry</i> , 2011 , 18, 4738-523		71
602	Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics. 2011 , 11, 2688-702		76
601	Studies on the biotransformations and biodistributions of metal-containing drugs using X-ray absorption spectroscopy. 2011 , 11, 553-71		45
600	Interactions of metal ions with DNA, its constituents and derivatives, which may be relevant for anticancer research. 2011 , 11, 2661-87		62
599	Cytotoxicity, apoptosis, cellular uptake, cell cycle arrest, photocleavage, and antioxidant activity of 1, 10-phenanthroline ruthenium(II) complexes. 2011 , 30, 839-48		17
598	Noble metal-dithiocarbamates precious allies in the fight against cancer. 2012 , 12, 1216-29		53
597	Next-generation anticancer metallodrugs. 2012 , 12, 219-35		163
596	Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form. <i>Journal of Inorganic Biochemistry</i> , 2012 , 116, 11-8	4.2	42
595	Transcription Inhibition by Organometallic Ruthenium - Arene Anticancer Complexes in Live Mammalian Cells. 2012 , 65, 1271		9
594	Thermodynamics of axial substitution and kinetics of reactions with amino acids for the paddlewheel complex tetrakis(acetato)chloridodiruthenium(II,III). 2012 , 51, 6615-25		23

593	Novel metal-based anticancer drugs: a new challenge in drug delivery. 2012 , 12, 420-6		60
592	Efficient DNA cleavage mediated by mononuclear mixed ligand copper(II) phenolate complexes: the role of co-ligand planarity on DNA binding and cleavage and anticancer activity. <i>Journal of Inorganic Biochemistry</i> , 2012 , 114, 94-105	4.2	102
591	Ruthenium (II) complexes binding to human serum albumin and inducing apoptosis of tumor cells. 2012 , 24, 104-109		17
590	Osmium(VI) nitrido complexes bearing azole heterocycles: a new class of antitumor agents. 2012 , 3, 1582		38
589	Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells. <i>Metallomics</i> , 2012 , 4, 1185-96	4.5	55
588	Synthesis, Characterization, DNA Binding, and Cleavage Activity of New Co(III) and Ru(II) Complexes of Substituted Quinolines. 2012 , 42, 518-524		7
587	Spectral characteristics, DNA-binding and cytotoxicity of two functional Ru(II) mixed-ligand complexes. <i>Dalton Transactions</i> , 2012 , 41, 4575-87	4.3	44
586	Investigation of the reactivity between a ruthenium hexacationic prism and biological ligands. 2012 , 51, 1057-67		62
585	Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin. 2012 , 51, 954-66		60
584	Biological activity of ruthenium nitrosyl complexes. 2012 , 26, 38-53		132
583	Synthesis and characterization of a diruthenium(II,III)ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives. 2012 , 42, 175-181		25
582	Naphthalimide-Tagged RutheniumArene Anticancer Complexes: Combining Coordination with Intercalation. 2012 , 31, 7031-7039		130
581	Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties. <i>Journal of Inorganic Biochemistry</i> , 2012 , 113, 77-82	4.2	23
580	Synthesis and structural characterization of new piano-stool ruthenium(II) complexes bearing 1-butylimidazole heteroaromatic ligand. 2012 , 713, 112-122		3
579	Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer. 2012 , 18, 14464-72		21
578	Delivery of floxuridine derivatives to cancer cells by water-soluble organometallic cages. 2012 , 23, 461-71		68
577	Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage. <i>Dalton Transactions</i> , 2012 , 41, 7201-11	4.3	49
576	Mixed ligand copper(II) complexes of N,N-bis(benzimidazol-2-ylmethyl)amine (BBA) with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity. 2012 , 51, 5512-32		175

575	New Directions in the Fight against Cancer: From Metal Complexes to Nanostructured Materials. 2012 , 207-242		2
574	Redox activation of metal-based prodrugs as a strategy for drug delivery. 2012 , 64, 993-1004		377
573	Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. 2012 , 84, 1428-36		51
572	Structural approaches to probing metal interaction with proteins. <i>Journal of Inorganic Biochemistry</i> , 2012 , 115, 138-47	4.2	14
571	Synthesis of organometallic ruthenium(II) complexes with strong activity against several human cancer cell lines. <i>Journal of Inorganic Biochemistry</i> , 2012 , 114, 65-74	4.2	45
570	Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2012 , 116, 180-7	4.2	52
569	Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents. <i>Dalton Transactions</i> , 2012 , 41, 13800-2	4.3	71
568	Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex. 2012 , 31, 5867-5874		53
567	Photocytotoxic lanthanide complexes. 2012 , 124, 1327-1342		28
566	Synthesis, crystal structure and biological studies of the highly anticancer active compound trans-dichloridobis(4-methyl-2-N-(2-pyridylmethylene)-aminophenol)ruthenium(II). 2012 , 393, 239-245		9
565	Anticancer Activity of Self-Assembled Molecular Rectangles via Arene-Ruthenium Acceptors and a New Unsymmetrical Amide Ligand. 2012 , 31, 3519-3526		71
564	Binding of anticancer drug Ru(II-C ₆ H ₅ (CH ₂) ₂ OH)Cl ₂ (DAPTA) to DNA purine bases and amino acid residues: a theoretical study. 2012 , 23, 1931-1940		4
563	A new promising application for highly cytotoxic metal compounds: π -areneruthenium(II) phosphite complexes for the treatment of alveolar echinococcosis. 2012 , 55, 4178-88		39
562	The contrasting chemical reactivity of potent isoelectronic iminopyridine and azopyridine osmium(II) arene anticancer complexes. 2012 , 3, 2485		84
561	Metals in Medicine and Metals as Drugs. 2012 , 415-432		1
560	Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells. <i>Metallomics</i> , 2012 , 4, 1051-6, 1007	4.5	85
559	Structure-activity relationships of targeted Ru(II)(π -p-cymene) anticancer complexes with flavonol-derived ligands. 2012 , 55, 10512-22		119
558	Binding and fluorescence resonance energy transfer (FRET) of ruthenium(II)-bipyridine-calixarene system with proteins—experimental and docking studies. 2012 , 22, 1345-56		18

557	From metallodrugs to metallodendrimers for nanotherapy in oncology: a concise overview. <i>Current Medicinal Chemistry</i> , 2012 , 19, 4995-5010	4-3	47
556	Modulating the activity of short arginine-tryptophan containing antibacterial peptides with N-terminal metallocenoyl groups. 2012 , 8, 1753-64		52
555	Synthesis, Characterization, DNA-binding Properties, and Antioxidant Activity of a Copper(II) Complex with 1, 3-Bis[1-allylbenzimidazol-2-yl]-2-oxopropane. 2012 , 638, 443-450		7
554	Metalation of Pyrazoles and Indazoles. 2012 , 155-260		12
553	Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications. 2012 , 33, 622-34		21
552	Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. 2012 , 51, 3633-9		46
551	Anticancer activity of silver-N-heterocyclic carbene complexes: caspase-independent induction of apoptosis via mitochondrial apoptosis-inducing factor (AIF). 2012 , 7, 805-14		104
550	Indazole: a medicinally important heterocyclic moiety. 2012 , 21, 1509-1523		95
549	Induction of cell cycle arrest and apoptosis by ruthenium complex cis-(dichloro)tetramineruthenium(III) chloride in human lung carcinoma cells A549. 2012 , 147, 8-15		19
548	Synthesis of [Ru(II)(η -p-cymene)(PPh ₃)(L)Cl]PF ₆ complexes with carbohydrate-derived phosphites, imidazole or indazole co-ligands. 2012 , 380, 211-215		10
547	Chelating behavior and biocidal efficiency of tryptophan based mixed-ligand complexes. 2012 , 20, 238-242		7
546	A novel Ru(II) complex derived from hydroxydiamine as a potential antitumor agent: Synthesis and Structural Characterization. 2012 , 20, 252-258		13
545	Synthesis, characterization, DNA-binding and cytotoxic properties of Ru(II) complexes: [Ru(Melm) ₄ L] ₂ ⁺ (Melm=1-methylimidazole, L=phen, ip and pip). 2012 , 1019, 183-190		12
544	Ruthenium(II) complexes with 2-(diphenylphosphinomethyl)aniline. 2012 , 34, 108-113		2
543	Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. <i>Journal of Inorganic Biochemistry</i> , 2012 , 106, 90-9	4.2	420
542	New η -arene ruthenium(II) piano-stool complexes with nitrogen ligands. <i>Journal of Inorganic Biochemistry</i> , 2012 , 109, 72-81	4.2	21
541	Synthesis, characterization, and anticancer activity of ruthenium-pyrazole complexes. <i>Journal of Inorganic Biochemistry</i> , 2012 , 111, 33-9	4.2	26
540	Chiral ruthenium complexes induce apoptosis of tumor cell and interact with bovine serum albumin. 2012 , 24, 174-80		6

539	Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. 2012 , 17, 409-23		107
538	Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends. 2013 , 405, 1791-808		55
537	Synthesis, characterization and X-ray crystal structures of ruthenium polypyridyl and 2-(2'-hydroxyphenyl)-benzoxazole complexes: Reactivity with 1-methylimidazole, purine, glutathione and CT-DNA. 2013 , 62, 148-157		5
536	Antitumor activity of new enantiopure pybox-ruthenium complexes. <i>Dalton Transactions</i> , 2013 , 42, 13955-67		15
535	Anticancer potency and multidrug-resistant studies of self-assembled arene-ruthenium metallarectangles. 2013 , 19, 11622-8		47
534	Biodistribution of Metals and Metallodrugs. 2013 , 933-949		3
533	NMR kinetic studies of the interactions between [Ru(terpy)(bipy)(H ₂ O)] ²⁺ and some sulfur-donor ligands. 2013 , 394, 552-557		7
532	Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. 2013 , 18, 9-17		104
531	X-ray crystal structure of rac-[Ru(phen)2dppz] ²⁺ with d(ATGCAT) ₂ shows enantiomer orientations and water ordering. 2013 , 135, 12652-9		74
530	Kinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents. <i>Dalton Transactions</i> , 2013 , 42, 16796-805	4.3	20
529	Interaction of vanadium(IV) with human serum apo-transferrin. <i>Journal of Inorganic Biochemistry</i> , 2013 , 121, 187-95	4.2	60
528	Cadmium complexes and cocrystals of indium complexes of benzothiazole derivatives and anticancer activities of the cadmium complexes. 2013 , 54, 285-293		33
527	Influence of carboxylic acid functionalities in ruthenium (II) polypyridyl complexes on DNA binding, cytotoxicity and antioxidant activity: synthesis, structure and in vitro anticancer activity. <i>European Journal of Medicinal Chemistry</i> , 2013 , 59, 253-64	6.8	48
526	Metallomics for drug development: an integrated CE-ICP-MS and ICP-MS approach reveals the speciation changes for an investigational ruthenium(III) drug bound to holo-transferrin in simulated cancer cytosol. <i>Metallomics</i> , 2013 , 5, 955-63	4.5	31
525	Synthesis, characterization and in vitro anticancer activity of highly cytotoxic trithiolato diruthenium complexes of the type [(16-p-MeC ₆ H ₄ iPr) ₂ Ru ₂ (2-SR1) ₂ (2-SR2)] ⁺ containing different thiolato bridges. 2013 , 744, 41-48		46
524	Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. 2013 , 135, 14060-3		72
523	Synthesis, characterization, and anticancer activity of a series of ketone-N(4)-substituted thiosemicarbazones and their ruthenium(II) arene complexes. 2013 , 52, 12440-9		59
522	Important cytotoxicity of novel iron(II) cyclopentadienyl complexes with imidazole based ligands. <i>Journal of Inorganic Biochemistry</i> , 2013 , 129, 1-8	4.2	26

521	X-ray fluorescence imaging of single human cancer cells reveals that the N-heterocyclic ligands of iodinated analogues of ruthenium anticancer drugs remain coordinated after cellular uptake. 2013 , 18, 845-53		19
520	Synthesis, characterization, DNA interaction, antioxidant and anticancer activity of new ruthenium(II) complexes of thiosemicarbazone/semicarbazone bearing 9,10-phenanthrenequinone. 2013 , 129, 17-26		53
519	Synthesis, characterization, and anticancer activity of ruthenium(II)-tarboline complex. <i>European Journal of Medicinal Chemistry</i> , 2013 , 70, 120-9	6.8	37
518	Synthesis and antitumor activity of a series of osmium(VI) nitrido complexes bearing quinolinolato ligands. 2013 , 49, 9980-2		28
517	Syntheses, characterization and molecular structures of novel Ru(II), Rh(III) and Ir(III) complexes and their possible roles as antitumour and cytotoxic agents. <i>New Journal of Chemistry</i> , 2013 , 37, 2573	3.6	24
516	The influence of RAPTA moieties on the antiproliferative activity of peripheral-functionalised poly(salicylaldiminato) metallodendrimers. <i>Dalton Transactions</i> , 2013 , 42, 1267-77	4.3	52
515	The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro. <i>Metallomics</i> , 2013 , 5, 597-614	4.5	55
514	Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(III) complexes with bulky triazolopyrimidine ligands. <i>Dalton Transactions</i> , 2013 , 42, 6219-26	4.3	50
513	X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). 2013 , 56, 1182-96		46
512	Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents. <i>Dalton Transactions</i> , 2013 , 42, 3771-4	4.3	24
511	Novel Organoruthenium(II) β -diketonates as Catalysts for Ortho Arylation via C-H Activation. 2013 , 32, 609-616		14
510	Design, synthesis and crystal structure determination of dinuclear copper-based potential chemotherapeutic drug entities; in vitro DNA binding, cleavage studies and an evaluation of genotoxicity by micronucleus test and comet assay. 2013 , 4, 394-405		31
509	Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death. <i>Dalton Transactions</i> , 2013 , 42, 2347-50	4.3	38
508	Interactions of Metal Ions with DNA and Some Applications. 2013 , 23, 4-23		71
507	The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. 2013 , 49, 3366-75		61
506	Neutral and cationic multinuclear half-sandwich rhodium and iridium complexes coordinated to poly(propyleneimine) dendritic scaffolds: Synthesis and cytotoxicity. 2013 , 729, 20-27		58
505	Solution equilibrium studies on anticancer ruthenium(II)-p-cymene complexes of 3-hydroxy-2(1H)-pyridones. 2013 , 734, 38-44		19
504	Synthesis, characterization, electrochemical behavior and in vitro protein tyrosine kinase inhibitory activity of the cymene-halogenobenzohydroxamato [Ru(η -p-cymene)(bha)Cl] complexes. 2013 , 730, 137-143		5

503	Biological activity of neutral and cationic iridium(III) complexes with P and P,S coordinated PhPCHB(O)xPh (x = 0-2) ligands. <i>European Journal of Medicinal Chemistry</i> , 2013 , 69, 216-22	6.8	16
502	The path for metal complexes to a DNA target. 2013 , 49, 3617-30		272
501	Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells. 2013 , 52, 5328-38		92
500	On the Electronic Structure of mer,trans-[RuCl3(1H-indazole)2(NO)], a Hypothetical Metabolite of the Antitumor Drug Candidate KP1019: An Experimental and DFT Study. 2013 , 2013, 2505-2519		17
499	3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands. <i>Dalton Transactions</i> , 2013 , 42, 6193-202	4.3	71
498	Anticancer cyclometalated complexes of platinum group metals and gold. <i>Coordination Chemistry Reviews</i> , 2013 , 257, 2784-2797	23.2	255
497	Organoruthenium antagonists of human A1 adenosine receptors. 2013 , 19, 8321-30		15
496	Theoretical evidence of photo-induced charge transfer from DNA to intercalated ruthenium (II) organometallic complexes. 2013 , 578, 133-137		44
495	Bis- and tris(2,3-dihydro-4a,12b-(epoxyethanoxy)[1,4]dioxino[2,3-f][1,10]phenanthroline) complexes of Ru(II): Synthesis, structure and DNA binding properties. 2013 , 1040, 98-111		11
494	Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes withazole heterocycles. 2013 , 52, 6273-85		36
493	Ruthenium(II) complexes of 2,2'-bipyridine-5,5'-dicarboxylic acid: Synthesis, structure, DNA binding, cytotoxicity and antioxidant activity. 2013 , 404, 58-67		11
492	A new family of Ru(II) complexes with a tridentate pyridine Schiff-base ligand and bidentate co-ligands: synthesis, characterization, structure and in vitro cytotoxicity studies. <i>New Journal of Chemistry</i> , 2013 , 37, 3450	3.6	30
491	Structure of NH-benzazoles (1H-benzimidazoles, 1H- and 2H-indazoles, 1H- and 2H-benzotriazoles). 2013 , 49, 177-202		21
490	Cytotoxicities of Polysubstituted Chlorodicarbonyl(cyclopentadienyl) and (Indenyl)ruthenium Complexes. 2013 , 32, 3012-3017		4
489	Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes. <i>Journal of Inorganic Biochemistry</i> , 2013 , 118, 83-93	4.2	78
488	Ru-TAP complexes and DNA: from photo-induced electron transfer to gene photo-silencing in living cells. 2013 , 371, 20120131		29
487	Synthesis, characterization, antioxidant, cytotoxic, and DNA cleavage studies of ruthenium(III) complexes containing N-substituted thiosemicarbazone/semicarbazone. 2013 , 144, 1787-1795		5
486	EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds. <i>Metallomics</i> , 2013 , 5, 1624-33	4.5	35

485	Antitumoral Gold and Silver Complexes with Ferrocenyl-Amide Phosphines. 2013 , 32, 6069-6078	52
484	In vitro effects of novel ruthenium complexes in <i>Neospora caninum</i> and <i>Toxoplasma gondii</i> tachyzoites. 2013 , 57, 5747-54	27
483	Novel microwave synthesis of half-sandwich $[(\eta^5\text{-C}_6\text{H}_6)\text{Ru}]$ complexes and an evaluation of the biological activity and biochemical reactivity. 2013 , 27, 425-434	10
482	Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions. 2013 , 19, 17031-42	49
481	Cytotoxicity of cyclometallated ruthenium complexes: the role of ligand exchange on the activity. 2013 , 371, 20120135	30
480	Synthesis, Characterization, and Biological Studies of New Ruthenium Polypyridyl Complexes Containing Noninnocent Ligands. 2013 , 2013, 1-6	1
479	Recent advances in multinuclear complexes as potential anticancer and DNA binding agents. 2014 , 14, 147-69	27
478	Apoptosis in BEL-7402 cells induced by ruthenium(II) complexes through a ROS-mediated mitochondrial pathway. 2014 , 39, 849-858	6
477	The H.G. Smith Award Article: Fluorescent Analogues of NAMI-A: Synthesis, Characterisation, Fluorescent Properties, and Preliminary Biological Studies in Human Lung Cancer Cells. 2014 , 67, 1711	2
476	In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex $[\text{Ru}(\eta^5\text{-p-cymene})\text{Cl}_2(\text{pta})]$ (RAPTA-C) in human ovarian and colorectal carcinomas. 2014 , 5, 4742-4748	188
475	In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. 2014 , 57, 9995-10012	71
474	Protein tyrosine phosphatase inhibition by metals and metal complexes. 2014 , 20, 2210-24	31
473	Cytotoxic triosmium carbonyl clusters: a structure-activity relationship study. 2014 , 9, 1453-7	22
472	Mechanistic Aspects of Ligand Substitution on cis-diaqua-chloro-tris(Dimethyl Sulfoxide) Ruthenium(II) Complex by Adenosine and Cytidine in Aqueous Medium. 2014 , 39, 74-88	1
471	Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes. 2014 , 19, 853-67	42
470	UV-vis absorption spectrum of a novel Ru(II) complex intercalated in DNA: $[\text{Ru}(2,2'\text{-bipy})(\text{dppz})(2,2'\text{-ArPy})]^+$. 2014 , 20, 2082	16
469	Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity. <i>European Journal of Medicinal Chemistry</i> , 2014 , 77, 110-20	6.8 16
468	Ruthenium Anticancer Compounds with Biologically-derived Ligands. 2014 , 405-437	4

467	Base-Catalyzed Hydrolysis of a Ru(II) Chloro-DMSO Complex and Its Reactivity towards L-Methionine. 2014 , 2014, 1333-1344	4
466	Anti-cancer drug KP1019 induces Hog1 phosphorylation and protein ubiquitylation in <i>Saccharomyces cerevisiae</i> . 2014 , 736, 77-85	18
465	Arene-ruthenium(II) acylpyrazolonato complexes: apoptosis-promoting effects on human cancer cells. 2014 , 57, 4532-42	67
464	Phenanthroline ligands are biologically more active than their corresponding ruthenium(II) arene complexes. <i>Dalton Transactions</i> , 2014 , 43, 2629-45	4-3 30
463	Opening the lid on piano-stool complexes: An account of ruthenium(II) arene complexes with medicinal applications. 2014 , 751, 251-260	206
462	Metallo drugs in medicinal inorganic chemistry. 2014 , 114, 4540-63	741
461	DNA interaction, antioxidant, and in vitro antitumor activity of binuclear ruthenium(III) complexes of benzothiazole-substituted ferrocenyl thiosemicarbazones. 2014 , 23, 958-968	11
460	2,3-Dihydroimidazo[1,2-b]ferroceno[d]pyridazines and a 3,4-dihydro-2H-pyrimido[1,2-b]ferroceno[d]pyridazine: Synthesis, structure and in vitro antiproliferation activity on selected human cancer cell lines. 2014 , 750, 41-48	16
459	Rhodium, iridium, and ruthenium half-sandwich picolinamide complexes as anticancer agents. 2014 , 53, 727-36	101
458	Substitution-Modulated Anticancer Activity of Half-Sandwich Ruthenium(II) Complexes with Heterocyclic Ancillary Ligands. 2014 , 2014, 3536-3546	16
457	Binuclear ruthenium complexes containing mPTA and alkyl-bis(8-thiotheophylline) derivatives (mPTA = N-methyl-1,3,5-triaza-7-phosphaadamantane). 2014 , 67, 2701-2710	3
456	Benzyl-substituted metallocarbene antibiotics and anticancer drugs. <i>Dalton Transactions</i> , 2014 , 43, 8144-53	51
455	Evaluation of the in vitro anticancer activity of cyclometalated half-sandwich rhodium and iridium complexes coordinated to naphthalaldimine-based poly(propyleneimine) dendritic scaffolds. 2014 , 774, 79-85	21
454	Metallomics for drug development: a further insight into intracellular activation chemistry of a ruthenium(III)-based anticancer drug gained using a multidimensional analytical approach. <i>Metallomics</i> , 2014 , 6, 147-53	4-5 25
453	Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme. <i>Dalton Transactions</i> , 2014 , 43, 6128-31	4-3 50
452	Kinetics and mechanistic investigation into the possible activation of imidazolium trans-[tetrachloridodimethylsulfoxideimidazoliruthenate(III)], NAMI-A, by 2-mercaptoethane sulfonate. <i>Dalton Transactions</i> , 2014 , 43, 12943-51	4-3 7
451	New method for the speciation of ruthenium-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks. 2014 , 1371, 168-76	17
450	Synthesis, Spectral Characterization, DNA Binding, DNA Cleavage, and Antioxidant Studies of Ruthenium(III) Heterocyclic Thiosemicarbazone Complexes. 2014 , 44, 1261-1271	5

449	The study of reduced versus oxidized glutathione in cancer cell models employing isotopically labelled standards. 2014 , 6, 3086-3094		4
448	Luminescent ruthenium complexes for theranostic applications. 2014 , 57, 4906-15		38
447	Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters. 2014 , 53, 5150-8		33
446	Coordination-Driven Self-Assembly and Anticancer Potency Studies of AreneRuthenium-Based Molecular Metalla-Rectangles. 2014 , 33, 1144-1151		44
445	Evaluation of trimetallic Ru(II)- and Os(II)-Arene complexes as potential anticancer agents. 2014 , 772-773, 229-241		27
444	Interaction of the NAMI-A complex with nitric oxide under physiological conditions. <i>New Journal of Chemistry</i> , 2014 , 38, 3386-3394	3.6	16
443	A rhodium(III) complex inhibits LPS-induced nitric oxide production and angiogenic activity in cellulose. <i>Journal of Inorganic Biochemistry</i> , 2014 , 140, 23-8	4.2	14
442	Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. <i>Dalton Transactions</i> , 2014 , 43, 1096-104	4.3	31
441	The studies on bioactivity in vitro of ruthenium(II) polypyridyl complexes towards human lung carcinoma A549 cells. 2014 , 4, 40899-40906		22
440	Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing CN-Chelated and Pyridine Ligands. 2014 , 33, 5324-5333		89
439	Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells. 2014 , 3, 301		7
438	DNA intercalating Ru(II) polypyridyl complexes as effective photosensitizers in photodynamic therapy. 2014 , 20, 14421-36		143
437	Metals in medicine: metal-related diseases. 2014 , 19, 779-814		
436	Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru ₂ Cl(lbp) ₄], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo. 2014 , 19, 1025-35		18
435	The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549). 2014 , 27, 459-69		13
434	Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in <i>Saccharomyces cerevisiae</i> . 2014 , 588, 1044-52		21
433	Ruthenium(II)Arene RAPTA Type Complexes Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective Anticancer Activity. 2014 , 33, 3709-3715		136
432	Photophysical properties and in vitro cytotoxicity studies of new Ru(II) carbonyl complexes and mixed geometrical Ru(II)Ni(II) complex in HS-DNA/BSA protein and human lung (A549) and liver (HepG2) cells. 2014 , 4, 51850-51864		17

431	Cytotoxicity Studies of Cyclometallated Ruthenium(II) Compounds: New Applications for Ruthenium Dyes. 2014 , 33, 1100-1103		87
430	Anticancer potency studies of coordination driven self-assembled areneRu-based metalla-bowls. 2014 , 15, 695-700		31
429	Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing P and P,S-coordinated Ph ₂ PCH ₂ CH ₂ CH ₂ S(O) _x Ph (x=0-2) ligands. 2014 , 9, 1586-93		6
428	Anticancer Ruthenium(II)-p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives. 2014 , 33, 5546-5553		72
427	Interaction of ruthenium(II) and ruthenium(III) ions with 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one. 2014 , 67, 410-415		12
426	Neutral and cationic osmium(II)-arene metallodendrimers: Synthesis, characterisation and anticancer activity. 2014 , 409, 112-120		27
425	Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca ²⁺ translocation by sarco-endoplasmic reticulum Ca ²⁺ -ATPase (SERCA). 2014 , 9, 1660-4		15
424	Ferrocene and (arene)ruthenium(II) complexes of the natural anticancer naphthoquinone plumbagin with enhanced efficacy against resistant cancer cells and a genuine mode of action. <i>Journal of Inorganic Biochemistry</i> , 2014 , 138, 64-72	4.2	32
423	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. <i>Metallomics</i> , 2014 , 6, 1616-25	4.5	52
422	{Ru(CO) _x }-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. 2014 , 81, 227-237		18
421	Design and synthesis of new Zn(II) nalidixic acid-DACH based Topo-II inhibiting molecular entity: Chemotherapeutic potential validated by its in vitro binding profile, pBR322 cleavage activity and molecular docking studies with DNA and RNA molecular targets. 2014 , 421, 26-37		19
420	Metal-based 2,3-indolinedione derivatives as proteasome inhibitors and inducers of apoptosis in human cancer cells. 2014 , 34, 870-9		13
419	Spectroscopic and Molecular Dynamics Studies on Binding of Dimethylplatinum(II) Complex Drug to Human Serum Albumin. 2014 , 87, 1094-1100		2
418	A Dimetallic Osmium(II) Complex as a Potential Phototherapeutic Agent: Binding and Photocleavage Studies with Plasmid DNA. 2015 , 2015, 5551-5555		4
417	Anticancer Organometallic Osmium(II)-p-cymene Complexes. 2015 , 10, 1539-47		16
416	Differential Anticancer Activities of the Geometric Isomers of Dinuclear Iridium(III) Complexes. 2015 , 2015, 5694-5701		7
415	DNA Damage Response Checkpoint Activation Drives KP1019 Dependent Pre-Anaphase Cell Cycle Delay in <i>S. cerevisiae</i> . 2015 , 10, e0138085		7
414	Water-Soluble Ruthenium(II) Complexes with Chiral 4-(2,3-Dihydroxypropyl)-formamide Oxoaporphine (FOA): In Vitro and in Vivo Anticancer Activity by Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Induction of Tumor Cell Apoptosis. 2015 , 58, 4771-89		90

413	Ruthenium(II)-arene complexes with naphthalimide-tagged N,O- and N,N-chelating ligands: Synthesis and biological evaluation. 2015 , 434, 239-251	16
412	Real-Time Monitoring of Cancer Cell Metabolism for Drug Testing. 2015 ,	
411	Elemental and molecular mass spectrometric strategies for probing interactions between DNA and new Ru(II) complexes containing phosphane ligands and either a tris(pyrazol-1-yl)borate or a pyridine bis(oxazoline) ligand. 2015 , 30, 172-179	2
410	Anticancer activity studies of a ruthenium(II) polypyridyl complex against human hepatocellular (BEL-7402) cells. 2015 , 150, 127-34	11
409	Medicinal organometallic chemistry: An emerging strategy for the treatment of neglected tropical diseases. 2015 , 6, 1230-1243	33
408	A ruthenium(II) complex with the propionate ion: Synthesis, characterization and cytotoxic activity. 2015 , 18, 1313-1319	4
407	A shotgun metalloproteomic approach enables identification of proteins involved in the speciation of a ruthenium anticancer drug in the cytosol of cancer cells. 2015 , 140, 3492-9	11
406	Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. 2015 , 20, 89-99	42
405	Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity. 2015 , 80, 231-236	27
404	Synthesis and the characterization of Schiff-base copper complexes: Reactivity with DNA, 4-NPP and BNPP. 2015 , 428, 176-184	7
403	Combination of Ru(ii) complexes and light: new frontiers in cancer therapy. 2015 , 6, 2660-2686	398
402	Incorporating ruthenium into advanced drug delivery carriers: An innovative generation of chemotherapeutics. 2015 , 90, 1177-1195	36
401	Synthesis of a ruthenium(II) tryptophan-associated complex and biological evaluation against Ehrlich murine breast carcinoma. 2015 , 40, 1-10	17
400	Equilibrium, kinetic, and computational studies on the formation of Cu ²⁺ and Zn ²⁺ complexes with an indazole-containing azamacrocyclic scorpionand: evidence for metal-induced tautomerism. 2015 , 54, 1983-91	7
399	Crystal structure determination, spectroscopic characterization and biological profile of a tailored ionic molecular entity, Sn(IV) iminodiacetic acid/piperazinediium conjugate: in vitro DNA/RNA binding studies, Topo I inhibition activity, cytotoxic and systemic toxicity studies. 2015 , 5, 16250-16264	20
398	Synthesis and characterization of water-soluble, heteronuclear ruthenium(III)/ferrocene complexes and their interactions with biomolecules. <i>Journal of Inorganic Biochemistry</i> , 2015 , 145, 41-50	4.2 14
397	Synthesis, characterization, DNA/protein binding and in vitro cytotoxic evaluation of new Ru(III) complexes containing aroylhydrazone ligands: Does hydrogen bonding influence the coordination behavior of hydrazones?. 2015 , 429, 148-159	18
396	Binding of Ru(terpyridine)(pyridine)dipyridophenazine to DNA studied with polarized spectroscopy and calorimetry. <i>Dalton Transactions</i> , 2015 , 44, 3604-13	4.3 10

395	Orbital entanglement and CASSCF analysis of the Ru-NO bond in a Ruthenium nitrosyl complex. 2015 , 17, 14383-92		49
394	Reactivity of hexanuclear ruthenium metallaprisms towards nucleotides and a DNA decamer. 2015 , 20, 49-59		9
393	Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV-Vis absorption spectroscopy and ESI MS. 2015 , 28, 425-30		4
392	Synthesis and Antiproliferative Activity of New Ruthenium Complexes with Ethacrynic-Acid-Modified Pyridine and Triphenylphosphine Ligands. 2015 , 54, 6504-12		51
391	Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorinated Chains. 2015 , 12, 3089-96		25
390	Spectroscopic studies on interactions of the tetrakis(acetato)chloridodiruthenium(II,III) complex and the Ru ₂ (II,III)-NSAID-derived metallodrugs of ibuprofen and ketoprofen with human serum albumin. 2015 , 68, 3209-3228		12
389	Quantum Chemical Studies on Detail Mechanism of Nitrosylation of NAMI-A-HSA Adduct. 2015 , 119, 10456-65		3
388	The rational design of NAMI-A-loaded mesoporous silica nanoparticles as antiangiogenic nanosystems. 2015 , 3, 6338-6346		30
387	Design, synthesis, DNA-binding affinity, cytotoxicity, apoptosis, and cell cycle arrest of Ru(II) polypyridyl complexes. 2015 , 485, 49-58		25
386	Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy. <i>Dalton Transactions</i> , 2015 , 44, 17482-93	4-3	30
385	Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands. <i>Dalton Transactions</i> , 2015 , 44, 13100-11	4-3	29
384	Cyclopentadienyl-ruthenium(II) and iron(II) organometallic compounds with carbohydrate derivative ligands as good colorectal anticancer agents. 2015 , 58, 4339-47		63
383	Impact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin. 2015 , 20, 695-703		24
382	Crystallisation of an Unexpected Trinuclear Heteronuclear Carbosilane Congener of Ferroquine. 2015 , 45, 202-206		
381	Acetylacetonato chelated ruthenium organometallics incorporating iminephenol function: Spectroscopic, structural, electrochemical and cytotoxicity studies. 2015 , 430, 36-45		6
380	Coordination compounds in cancer: Past, present and perspectives. 2015 , 13, 79-103		87
379	New chloride-dimethylsulfoxide-iridium(III) complex with histaminium. 2015 , 102, 735-740		1
378	Further Insight into the Lability of MeCN Ligands of Cytotoxic Cycloruthenated Compounds: Evidence for the Antisymbiotic Effect Trans to the Carbon Atom at the Ru Center. 2015 , 54, 7617-26		11

377	Capillary electrophoresis in metallodrug development. 2015 , 16, 16-22		8
376	Potential anticancer activity of benzimidazole-based mono/dinuclear Zn(II) complexes towards human carcinoma cells. 2015 , 102, 163-172		12
375	Synthesis and characterization of ruthenium(II) hydrazone complexes as anticancer chemotherapeutic agents: in vitro DNA/BSA protein binding and cytotoxicity assay. 2015 , 68, 3551-3565		19
374	Anticancer Activity and Autophagy Involvement of Self-Assembled AreneRuthenium Metallacycles. 2015 , 34, 4507-4514		30
373	Ruthenium(II) p-cymene complex bearing 2,2'-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response. <i>Journal of Inorganic Biochemistry</i> , 2015 , 153, 315-321	4.2	23
372	The non-innocent nature of graphene oxide as a theranostic platform for biomedical applications and its reactivity towards metal-based anticancer drugs. 2015 , 5, 76556-76566		12
371	Ruthenium(II) polypyridyl complexes: synthesis, cytotoxicity in vitro, reactive oxygen species, mitochondrial membrane potential and cell cycle arrest studies. 2015 , 40, 153-160		5
370	Synthesis and characterization of the anticancer and metal binding properties of novel pyrimidinylhydrazone derivatives. <i>Journal of Inorganic Biochemistry</i> , 2015 , 144, 18-30	4.2	22
369	L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells. 2015 , 20, 109-21		12
368	Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity. <i>Dalton Transactions</i> , 2015 , 44, 1905-13	4.3	30
367	Cytotoxic peptide conjugates of dinuclear arene ruthenium trithiolato complexes. 2015 , 6, 347-350		15
366	Metallomic and metalloproteomic strategies in elucidating the molecular mechanisms of metallodrugs. <i>Dalton Transactions</i> , 2015 , 44, 437-47	4.3	32
365	Modulation of the A β peptide aggregation pathway by KP1019 limits A β associated neurotoxicity. <i>Metallomics</i> , 2015 , 7, 129-35	4.5	24
364	Metal complex interactions with DNA. <i>Dalton Transactions</i> , 2015 , 44, 3505-26	4.3	222
363	Spectroscopic investigation on the interaction of ruthenium complexes with tumor specific lectin, jacalin. 2015 , 137, 1292-7		10
362	Cytotoxic hydrogen bridged ruthenium quinaldamide complexes showing induced cancer cell death by apoptosis. <i>Dalton Transactions</i> , 2016 , 45, 13196-203	4.3	10
361	Anticancer activity studies of ruthenium(II) polypyridyl complexes against human gastric carcinoma SGC-7901 cell. 2016 , 70, 210-218		7
360	Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry. 2016 , 37, 959-72		19

359	Ester-Modified Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents. 2016 , 6, 38954		30
358	Synthesis of novel anticancer ruthenium-arene pyridinylmethylene scaffolds via three-component reaction. 2016 , 26, 2695-700		17
357	A comparative study on the interactions of human copper chaperone Cox17 with anticancer organoruthenium(II) complexes and cisplatin by mass spectrometry. <i>Journal of Inorganic Biochemistry</i> , 2016 , 161, 99-106	4-2	3
356	New $[(\eta^5\text{-C}_5\text{H}_5)\text{Ru}(\text{N-N})(\text{PPh}_3)][\text{PF}_6]$ compounds: colon anticancer activity and GLUT-mediated cellular uptake of carbohydrate-appended complexes. <i>Dalton Transactions</i> , 2016 , 45, 11926-30	4-3	14
355	Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II) Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines. 2016 , 55, 4595-605		35
354	Alteration of steric hindrance modulates glutathione resistance and cytotoxicity of three structurally related Ru(II)-p-cymene complexes. <i>Dalton Transactions</i> , 2016 , 45, 8541-55	4-3	20
353	Impact of chelation on anticancer activities of organometallic ruthenium(II) complexes containing 2,5-di(1H-pyrazol-1-yl)-1,4-benzoquinone: synthesis, structure, DNA/protein binding, antioxidant activity and cytotoxicity. 2016 , 6, 46531-46547		6
352	CF ₃ Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity. 2016 , 55, 4850-63		52
351	Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. 2016 , 8, 527-44		39
350	Supramolecular metalloglycodendrimers selectively modulate lectin binding and delivery of Ru(ii) complexes into mammalian cells. 2016 , 14, 10816-10821		4
349	Rational design of multi-targeting ruthenium- and platinum-based anticancer complexes. 2016 , 59, 1240-1249		13
348	N-Heterocyclic Carbene-Polyethylenimine Platinum Complexes with Potent in Vitro and in Vivo Antitumor Efficacy. 2016 , 27, 1942-8		24
347	Investigation of antitumor mechanism of the chiral ruthenium complex $[\text{Ru}(\text{phen})_2\text{p-MOPIP}]_2^+$ in human gastric cancer MGC-803 cells. 2016 , 72, 1-6		2
346	Interactions between proteins and Ru compounds of medicinal interest: A structural perspective. <i>Coordination Chemistry Reviews</i> , 2016 , 326, 111-134	23-2	85
345	Comparison of KP1019 and NAMI-A in tumour-mimetic environments. <i>Metallomics</i> , 2016 , 8, 762-73	4-5	31
344	Biological activity and binding properties of $[\text{Ru}(\text{II})(\text{dcbpy})_2\text{Cl}_2]$ complex to bovine serum albumin, phospholipase A2 and glutathione. 2016 , 29, 921-33		8
343	Design, syntheses, characterization, and cytotoxicity studies of novel heterobinuclear oxindolimine copper(II)-platinum(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2016 , 165, 108-118	4-2	9
342	Cyclometallated iridium complexes inducing paraptotic cell death like natural products: synthesis, structure and mechanistic aspects. <i>Dalton Transactions</i> , 2016 , 45, 15122-15136	4-3	36

341	Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates as ligands: Loading into nanocarriers and preliminary biological studies. <i>Journal of Inorganic Biochemistry</i> , 2016 , 165, 159-169	4.2	11
340	Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity. <i>Dalton Transactions</i> , 2016 , 45, 16913-16921	4.3	29
339	Arene ruthenium(II) complexes with chalcone, aminoantipyrine and aminopyrimidine based ligands: synthesis, structure and preliminary evaluation of anti-leukemia activity. 2016 , 6, 90982-90992		17
338	Synthesis, characterization, DNA binding, DNA cleavage, antioxidant and in vitro cytotoxicity studies of ruthenium(II) complexes containing hydrazone ligands. 2016 , 69, 3545-3559		9
337	Dual mode of cell death upon the photo-irradiation of a Ru polypyridyl complex in interphase or mitosis. 2016 , 7, 6115-6124		62
336	Axially-modified paddlewheel diruthenium(II,III)-ibuprofenato metallodrugs and the influence of the structural modification on U87MG and A172 human glioma cell proliferation, apoptosis, mitosis and migration. <i>Journal of Inorganic Biochemistry</i> , 2016 , 165, 181-191	4.2	22
335	Amberlite IR-120(H)-mediated β n water β synthesis of novel anticancer ruthenium(II) β -cymene 2-pyridinylbenzothiazole (BTZ), 2-pyridinylbenzoxazole (BOZ) & 2-pyridinylbenzimidazole (BIZ) scaffolds. <i>New Journal of Chemistry</i> , 2016 , 40, 10333-10343	3.6	19
334	Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes. 2016 , 6, 20596		41
333	Combining a Ru(ii)-arene complex with a NO-releasing nitrate-ester ligand generates cytotoxic activity. <i>Dalton Transactions</i> , 2016 , 45, 18079-18083	4.3	4
332	From Sunscreen to Anticancer Agent: Ruthenium(II) Arene Avobenzone Complexes Display Potent Anticancer Activity. 2016 , 35, 3734-3742		33
331	Ruthenium(II) complexes containing 4-methoxybenzhydrazone ligands: synthesis, characterization, DNA binding, DNA cleavage, radical scavenging and in vitro cytotoxic activity. 2016 , 30, 550-560		9
330	Nucleophilic substitution reactions of $[(\beta\text{-Cp}^*)\text{Ru}(\beta\text{-C}_6\text{H}_5\text{CO}_2\text{H})]^+$: Synthesis, characterization and cytotoxicity of organoruthenium ester and amide complexes. 2016 , 819, 1-10		5
329	Sulfonated Schiff base Sn(IV) complexes as potential anticancer agents. <i>Journal of Inorganic Biochemistry</i> , 2016 , 162, 83-95	4.2	31
328	DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes. <i>Dalton Transactions</i> , 2016 , 45, 4633-46	4.3	56
327	Nonsteroidal Anti-inflammatory-Organometallic Anticancer Compounds. 2016 , 55, 1788-808		54
326	Synthesis, characterisation, cytotoxicity and antibacterial activity of ruthenium(II) and rhodium(III) complexes with sulfur-containing terpyridines. 2016 , 107, 27-37		9
325	Studies on the bioactivities of 8-mercaptoquinoline sulfide derivatives. 2016 , 64, 7-12		3
324	$(\beta\text{-Arene})$ ruthenium complexes with P-coordinated phosphinoferrrocene amides bearing extended polar substituents at the amide nitrogen: Synthesis, characterization and cytotoxicity. 2016 , 802, 21-26		15

323	Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization. 2016 , 55, 177-90		26
322	Fluorescent active ruthenium(II) complex units containing bpy or phen or dmp ligands anchored on branched poly(ethylenimine): DNA binding and in vitro biological assessment. 2016 , 6, 31831-31839		5
321	Monitoring the DNA by ruthenium complexes of heterocyclic N,S-donor ligands and evaluation of biological activities. 2016 , 147, 1903-1914		2
320	A novel dual-functioning ruthenium(II)-arene complex of an anti-microbial ciprofloxacin derivative - Anti-proliferative and anti-microbial activity. <i>Journal of Inorganic Biochemistry</i> , 2016 , 160, 210-7	4.2	49
319	Increasing anti-cancer activity with longer tether lengths of group 9 Cp* complexes. <i>Dalton Transactions</i> , 2016 , 45, 6812-5	4.3	27
318	Synthesis, structure and anticancer activity of (η^6 -benzene) ruthenium(II) complexes containing aroylhydrazone ligands. 2016 , 807, 45-51		20
317	Synthesis, crystal structure and cytotoxic activity of ruthenium(II) piano-stool complex with N,N-chelating ligand. 2016 , 1126, 74-82		13
316	Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes. <i>Dalton Transactions</i> , 2016 , 45, 7049-66	4.3	52
315	Biological properties of novel ruthenium- and osmium-nitrosyl complexes withazole heterocycles. 2016 , 21, 347-56		20
314	Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action. <i>Journal of Inorganic Biochemistry</i> , 2016 , 160, 250-5	4.2	72
313	Synthesis, structural, DFT studies and antibacterial evaluation of Cp* rhodium and Cp* iridium complexes using hydrazide based dipyrityl ketone ligand. 2016 , 443, 126-135		12
312	Synthesis and Evaluation of In Vitro DNA/Protein Binding Affinity, Antimicrobial, Antioxidant and Antitumor Activity of Mononuclear Ru(II) Mixed Polypyridyl Complexes. 2016 , 26, 225-40		14
311	Interactions of two cytotoxic organoruthenium(II) complexes with G-quadruplex. <i>Journal of Inorganic Biochemistry</i> , 2016 , 160, 70-7	4.2	7
310	In vitro and in vivo evaluation of organometallic gold(I) derivatives as anticancer agents. <i>Dalton Transactions</i> , 2016 , 45, 2462-75	4.3	38
309	Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes. 2016 , 82, 663-70		23
308	Cationic Ru(II), Rh(III) and Ir(III) complexes containing cyclic -perimeter and 2-aminophenyl benzimidazole ligands: Synthesis, molecular structure, DNA and protein binding, cytotoxicity and anticancer activity. 2016 , 801, 68-79		50
307	The development of RAPTA compounds for the treatment of tumors. <i>Coordination Chemistry Reviews</i> , 2016 , 306, 86-114	23.2	320
306	Synthesis, characterization, X-ray structural determination and theoretical study of the complexes [RuCp(8MTT- β)LL?] \cdot (8MTT=8-methylthio-theophyllinate; L,L?=PTA, mPTA; L=mPTA, L?=PPh ₃ ; PTA=1,3,5-triaza-7-phosphaadamantane, mPTA=N-methyl-1,3,5-triaza-7-phosphaadamantane). 2017 , 455, 557-567		3

305	Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. 2017 , 7, 40966		21
304	Iron(III) Pincer Complexes as a Strategy for Anticancer Studies. 2017 , 2017, 1673-1678		21
303	Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity. 2017 , 839, 31-37		17
302	Combination of ruthenium(II)-arene complex [Ru(η^6 -cymene)Cl(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. 2017 , 7, 43005		78
301	Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os. 2017 , 23, 4893-4902		29
300	Two silver(I) complexes with bis(benzimidazole)-2-oxopropane ligands: Syntheses, crystal structures and DNA binding studies. 2017 , 31, e3747		15
299	Direct Determination of Metal Complexes' Interaction with DNA by Atomic Telemetry and Multiscale Molecular Dynamics. 2017 , 8, 805-811		16
298	(Pentamethylcyclopentadienato)rhodium Complexes for Delivery of the Curcumin Anticancer Drug. 2017 , 2017, 1812-1823		15
297	Synthesis, characterization and biological evaluation of ruthenium flavanol complexes against breast cancer. 2017 , 180, 97-104		16
296	Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. <i>European Journal of Medicinal Chemistry</i> , 2017 , 142, 8-31	6.8	217
295	Influence of Halogen Substitution in the Ligand Sphere on the Antitumor and Antibacterial Activity of Half-sandwich Ruthenium(II) Complexes [RuX(η^6 -arene)(C ₅ H ₄ N-2-CH=N-Ar)] ⁺ . 2017 , 643, 699-711		13
294	Expression proteomics study to determine metallodrug targets and optimal drug combinations. 2017 , 7, 1590		14
293	New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent. 2017 , 56, 5514-5518		43
292	Ruthenium(II) η^6 -Arene Metallacycles: Crystal Structures, Interaction with DNA, and Cytotoxicity. 2017 , 2017, 1792-1799		13
291	A general strategy to add diversity to ruthenium arene complexes with bioactive organic compounds via a coordinated (4-hydroxyphenyl)diphenylphosphine ligand. <i>Dalton Transactions</i> , 2017 , 46, 12001-12004	4.3	26
290	Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker-256 tumor-bearing rats. 2017 , 110, 228-239		13
289	Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells. 2017 , 56, 7519-7532		33
288	Synthesis, X-ray structure, in vitro HIV and kinesin Eg5 inhibition activities of new arene ruthenium complexes of pyrimidine analogs. 2017 , 70, 2061-2073		4

287	Unfolding biological properties of a versatile dicopper(II) precursor and its two mononuclear copper(II) derivatives. <i>Journal of Inorganic Biochemistry</i> , 2017 , 174, 25-36	4.2	7
286	Amidoxime platinum(II) complexes: pH-dependent highly selective generation and cytotoxic activity. <i>New Journal of Chemistry</i> , 2017 , 41, 6840-6848	3.6	8
285	Diruthenium(ii,iii) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells. 2017 , 9, 10701-10714		33
284	Functionalization of Ruthenium(II)(η -p-cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. 2017 , 82, 841-847		12
283	Defining the Anti-Cancer Activity of Tricarbonyl Rhenium Complexes: Induction of G2/M Cell Cycle Arrest and Blockade of Aurora-A Kinase Phosphorylation. 2017 , 23, 6518-6521		40
282	Ru(II) Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic. 2017 , 2017, 1100-1119		33
281	Synthesis of an organo-ruthenium aminoquinoline-trioxane hybrid and evaluation of its activity against Plasmodium falciparum and its toxicity toward normal mammalian cells. 2017 , 26, 473-483		10
280	Speciation of metal drugs, supplements and toxins in media and bodily fluids controls in vitro activities. <i>Coordination Chemistry Reviews</i> , 2017 , 352, 473-498	23.2	132
279	Electron Paramagnetic Resonance as a Tool for Studying the Mechanisms of Paramagnetic Anticancer Metallodrugs. 2017 , 2017, 1573-1585		18
278	Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. 2017 , 56, 528-541		42
277	Synthesis, Structure, Biological Evaluation, and Catalysis of Two Pyrazole-Functionalized NHC-Ru(II) Complexes. 2017 , 2017, 616-622		16
276	Targeting G-quadruplex DNA as Potential Anti-cancer Therapy. 2017 , 129-162		
275	Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates. 2017 , 46, 7317-7337		125
274	Potent Anticancer Activity with High Selectivity of a Chiral Palladium N-Heterocyclic Carbene Complex. 2017 , 2, 4632-4646		35
273	Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) β -carboline complexes. <i>European Journal of Medicinal Chemistry</i> , 2017 , 140, 104-117	6.8	35
272	In vitro antitumor activity of novel benzimidazole-based Cu(II) complexes. 2017 , 25, 5733-5742		13
271	Application of Metallomics and Metalloproteomics for Understanding the Molecular Mechanisms of Action of Metal-Based Drugs. 2017 , 199-222		
270	Structure and reactivities of rhenium and technetium bis-arene sandwich complexes [M(β -arene)]. <i>Dalton Transactions</i> , 2017 , 46, 14631-14637	4.3	16

269	Anticancer Agents Beyond Cisplatin. 2017 , 157-216		2
268	Essential and Non-essential Metals. 2017 ,		3
267	Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. 2017 , 404, 79-88		24
266	Influence of the Linker Length on the Cytotoxicity of Homobinuclear Ruthenium(II) and Gold(I) Complexes. 2017 , 56, 9617-9633		25
265	Varying the metal to ethacrynic acid ratio in ruthenium(ii)/osmium(ii)-p-cymene conjugates. <i>Journal of Inorganic Biochemistry</i> , 2017 , 175, 198-207	4.2	16
264	[Ru(pipe)(dppb)(bipy)]PF ₆ : A novel ruthenium complex that effectively inhibits ERK activation and cyclin D1 expression in A549 cells. 2017 , 44, 382-391		6
263	Ruthenium-Based Anticancer Compounds: Insights into Their Cellular Targeting and Mechanism of Action. 2017 , 201-219		2
262	Trends and Perspectives of Ruthenium Anticancer Compounds (Non-PDT). 2017 , 271-291		2
261	Ruthenium Anticancer Agents En Route to the Tumor. 2017 , 161-180		
260	Design Aspects of Ruthenium Complexes as DNA Probes and Therapeutic Agents. 2017 , 181-200		0
259	Structural feature of calf thymus deoxyribonucleic acid-Ruthenium(III) interaction in aqueous solution by difference Fourier transformed infrared spectroscopy. 2017 , 50, 426-431		2
258	Impact of aromaticity on anticancer activity of polypyridyl ruthenium(II) complexes: synthesis, structure, DNA/protein binding, lipophilicity and anticancer activity. 2017 , 22, 1007-1028		26
257	The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. 2017 , 46, 5771-5804		573
256	Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies. <i>Dalton Transactions</i> , 2017 , 46, 8539-8554	4.3	28
255	Mononuclear Pd(II) complex as a new therapeutic agent: Synthesis, characterization, biological activity, spectral and DNA binding approaches. 2017 , 1148, 339-346		16
254	Spectroscopic and cytotoxic characteristics of (p-cymene)Ru(II) complexes with bidentate coumarins and density functional theory comparison with selected Pd(II) complexes. 2017 , 456, 105-112		1
253	Cationic Ru(II)-p-cymene Complexes of 3-Hydroxy-4-pyr(id)ones [Lipophilic Triphenylphosphine as Co-Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents. 2017 , 2017, 1721-1727		22
252	2,2'- bipyridine coplanar with coordination square of Pd(II) nonylthiocarbamate antitumor complex interacting with DNA in two distinct steps. 2017 , 35, 2301-2313		7

251	Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective. 2017 , 2017, 1549-1560		236
250	Aqueous behavior and reactivity towards nitric oxide of NAMI-A type complexes bearing bulky N-heterocyclic ligands. 2017 , 460, 119-126		4
249	Liposome-based drug co-delivery systems in cancer cells. 2017 , 71, 1327-1341		177
248	. 2017 ,		20
247	Nanoformulation as a Tool for Improve the Pharmacological Profile of Platinum and Ruthenium Anticancer Drugs. 2017 ,		1
246	Synthesis, Characterization, Cytotoxic Activity, and Interactions with CT-DNA and BSA of Cationic Ruthenium(II) Complexes Containing Dppm and Quinoline Carboxylates. 2017 , 2017, 2562780		5
245	Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells. 2017 , 12, e0183275		38
244	Synthesis and In Vitro (Anticancer) Evaluation of β -Arene Ruthenium Complexes Bearing Stannyl Ligands. 2017 , 5, 44		9
243	A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. 2017 , 8, 2568-2584		37
242	Flexible ligated ruthenium(II) self-assemblies sensitizes glioma tumor initiating cells. 2017 , 8, 60188-60200		4
241	A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A). 2017 , 8, 98426-98454		13
240	N- and S-donor leaving groups in triazole-based ruthena(ii)cycles: potent anticancer activity, selective activation, and mode of action studies. <i>Dalton Transactions</i> , 2018 , 47, 4625-4638	4.3	16
239	Ru(III)MSO complexes containingazole-based ligands: synthesis and cytotoxicity study. <i>New Journal of Chemistry</i> , 2018 , 42, 6858-6866	3.6	1
238	Development of medical drugs: Synthesis and in vitro bio-evaluations of nanomedicinal zincpenicillins polymeric hydrogel membranes for wound skin dressing by new chemical technology. 2018 , 255, 462-470		9
237	The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?. 2018 , 18,		15
236	Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?. 2018 , 61, 5805-5821		238
235	Anticancer Activity of Bifunctional Organometallic Ru(II) Arene Complexes Containing a 7-Hydroxycoumarin Group. 2018 , 37, 441-447		33
234	Analysis of ruthenium anticancer agents by MEEKC-UV and MEEKC-ICP-MS: Impact of structural motifs on lipophilicity and biological activity. 2018 , 39, 1201-1207		13

233	Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. 2018 , 416, 138-148		20
232	Kinetically-inert polypyridylruthenium(II) complexes as therapeutic agents. <i>Coordination Chemistry Reviews</i> , 2018 , 375, 134-147	23.2	27
231	Harnessing ruthenium(II) as photodynamic agents: Encouraging advances in cancer therapy. <i>Coordination Chemistry Reviews</i> , 2018 , 363, 17-28	23.2	105
230	Octahedral Co(III) salen complexes: the role of peripheral ligand electronics on axial ligand release upon reduction. 2018 , 96, 110-118		4
229	New Ru(II) complexes containing tris(2-pyridylmethyl)amine. Synthesis, structural, CT-DNA/albumin interaction, anti-oxidant and cytotoxicity studies. 2018 , 471, 724-734		10
228	Organometallic ruthenium(II) complexes containing NS donor Schiff bases: Synthesis, structure, electrochemistry, DNA/BSA binding, DNA cleavage, radical scavenging and antibacterial activities. 2018 , 854, 1-14		27
227	Mechanistic Aspects of Ligand Substitution on the Cis-Diaqua-Chloro-Tris(Dimethyl Sulfoxide)Ruthenium(II) Complex by Some Sulfur-Containing Bioactive Ligands in Aqueous Medium. 2018 , 43, 274-285		
226	Impact of copper and iron binding properties on the anticancer activity of 8-hydroxyquinoline derived Mannich bases. <i>Dalton Transactions</i> , 2018 , 47, 17032-17045	4.3	18
225	From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents. 2018 , 57, 14427-14434		38
224	Applications of Ruthenium Complex in Tumor Diagnosis and Therapy. 2018 , 9, 1323		56
223	Activation by Oxidation: Ferrocene-Functionalized Ru(II)-Arene Complexes with Anticancer, Antibacterial, and Antioxidant Properties. 2018 , 57, 15247-15261		33
222	Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions. 2018 , 19, 937-947		7
221	Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers. 2018 , 140, 14367-14380		53
220	Ionic π -Cp-Ruthenium (II) complexes as potential anticancer agents. 2018 , 875, 29-34		1
219	Synthesis and Characterization of -Dichlorotetrakis(imidazole)cobalt(III) Chloride: A New Cobalt(III) Coordination Complex with Potential Prodrug Properties. 2018 , 2018, 4560757		1
218	Hypoxia-Targeting Organometallic Ru(II)-Arene Complexes with Enhanced Anticancer Activity in Hypoxic Cancer Cells. 2018 , 57, 8396-8403		25
217	Mitochondria-targeted half-sandwich ruthenium(II) diimine complexes: anticancer and antimetastasis via ROS-mediated signalling. 2018 , 5, 2100-2105		49
216	Understanding the interactions of diruthenium anticancer agents with amino acids. 2018 , 23, 1159-1164		7

215	BODIPY-based Ir(III) rectangles containing bis-benzimidazole ligands with highly selective toxicity obtained through self-assembly. 2018 , 868, 86-94		13
214	BODIPY-based Ru(II) and Ir(III) organometallic complexes of avobenzone, a sunscreen material: Potent anticancer agents. <i>Journal of Inorganic Biochemistry</i> , 2018 , 189, 17-29	4.2	28
213	Synthesis, physicochemical and theoretical studies on new rhodium and ruthenium dimers. Relationship between structure and cytotoxic activity. 2018 , 154, 263-274		5
212	Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium. <i>Dalton Transactions</i> , 2018 , 47, 9934-9974	4.3	138
211	Metals in Medicine and Metals as Drugs. 2019 , 599-623		1
210	Synthesis and preliminary biological evaluation for the anticancer activity of organochalcogen (S/se) tethered chrysin-based organometallic Ru(η -p-cymene) complexes. 2019 , 37, 3337-3353		7
209	Anticancer, antifungal and antibacterial potential of bis(η -ketoiminato)ruthenium(II) carbonyl complexes. 2019 , 498, 119025		4
208	Screening and Preliminary Biochemical and Biological Studies of [RuCl(-cymene)(η -bis(diphenylphosphino)-isopropylamine)][BF ₄] in Breast Cancer Models. 2019 , 4, 13005-13014		2
207	Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: a comparative study. 2019 , 24, 703-719		24
206	Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy. 2019 , 55, 9904-9914		54
205	Modulation of ruthenium anticancer drugs analogs with tolfenamic acid: Reactivity, biological interactions and growth inhibition of yeast cell. <i>Journal of Inorganic Biochemistry</i> , 2019 , 199, 110769	4.2	7
204	Luminescent anticancer ruthenium(II)-p-cymene complexes of extended imidazophenanthroline ligands: synthesis, structure, reactivity, biomolecular interactions and live cell imaging. <i>Dalton Transactions</i> , 2019 , 48, 12257-12271	4.3	22
203	Ruthenium Complexes Containing Heterocyclic Thioamidates Trigger Caspase-Mediated Apoptosis Through MAPK Signaling in Human Hepatocellular Carcinoma Cells. 2019 , 9, 562		9
202	Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies. 2019 , 2, 1900042		32
201	CpRu Complexes Containing Water Soluble Phosphane PTA and Natural Purines Adenine, Guanine and Theophylline: Synthesis, Characterization, and Antiproliferative Properties. 2019 , 2019, 4078-4086		6
200	Improved Synthesis, Anticancer Activity and Electrochemical Characterization of Unusual Zwitterionic Palladium Compounds with a Ten-Term Coordinative Ring.. 2019 , 4, 10911-10919		6
199	Induction of Apoptosis in SKOV3 and DNA Binding by Cobalt(III) Polypyridyl Complexes. 2019 , 45, 273-284		2
198	The nickel-catalyzed C3-acylation of 2H-indazoles with aldehydes. 2019 , 17, 8749-8755		10

197	Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity. <i>Pharmaceuticals</i> , 2019 , 12,	5.2	33
196	Multifunctional, heterometallic ruthenium-platinum complexes with medicinal applications. <i>Coordination Chemistry Reviews</i> , 2019 , 401, 213067	23.2	13
195	Design, Synthesis, Characterization and Antiproliferative Activities of Ru(II) Complexes of Substituted Benzimidazoles. 2019 , 31, 2311-2318		
194	The hydrolysis of a ruthenium(III) complex with triazolopyrimidine ligands and mechanistic insights into its anticancer activity. 2019 , 109, 107567		1
193	Heterobimetallic Ru(Edppm)Fe and homobimetallic Ru(Edppm)Ru complexes as potential anti-cancer agents. 2019 , 901, 120934		11
192	Cytotoxic Ru-p-cymene complexes of an anthraimidazoleione: halide dependent solution stability, reactivity and resistance to hypoxia deactivation. <i>Dalton Transactions</i> , 2019 , 48, 7187-7197	4.3	13
191	Synthesis, characterisation, molecular docking, biomolecular interaction and cytotoxicity studies of novel ruthenium(II)Brene-2-heteroarylbenzoxazole complexes. <i>New Journal of Chemistry</i> , 2019 , 43, 3291-3302	3.6	19
190	Anticancer and Antibacterial Activity of Transition Metal Complexes. 2019 , 4, 1706-1721		21
189	A Ru(II)-p-cymene compound bearing naproxen-pyridineamide. Synthesis, spectroscopic studies, computational analysis and in vitro anticancer activity against lung cells compared to Ru(II)-p-cymene-naproxen and the corresponding drug ligands. 2019 , 489, 27-38		10
188	A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles. 2019 , 7, 1652-1660		17
187	Hypoxia-targeted drug delivery. 2019 , 48, 771-813		210
186	Organoruthenium(II) nucleoside conjugates as colon cytotoxic agents. <i>New Journal of Chemistry</i> , 2019 , 43, 1195-1201	3.6	2
185	High in Vitro and in Vivo Tumor-Selective Novel Ruthenium(II) Complexes with 3-(2'-Benzimidazolyl)-7-fluoro-coumarin. 2019 , 10, 936-940		28
184	NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. 2019 , 24,		138
183	Induction of transferrin aggregation by indazolium [tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) and its biological function. <i>New Journal of Chemistry</i> , 2019 , 43, 11296-11306	3.6	3
182	A Proteomic View of Cellular Responses to Anticancer Quinoline-Copper Complexes. 2019 , 7,		10
181	Cyclometallated ruthenium complexes with P-stereogenic monophosphines containing a polycyclic aromatic substituent. 2019 , 896, 51-58		4
180	New Heteroleptic Ruthenium(II) Complexes with Sulfamethoxypyridazine and Diimines as Potential Antitumor Agents. 2019 , 24,		3

179	Organometallic Iridium Arene Compounds: The Effects of C-Donor Ligands on Anticancer Activity. 2019 , 48, 916-924		14
178	Type of complex BSA binding forces affected by different coordination modes of alliin in novel water-soluble ruthenium complexes. <i>New Journal of Chemistry</i> , 2019 , 43, 5791-5804	3.6	9
177	Polymer encapsulation of ruthenium complexes for biological and medicinal applications. 2019 , 3, 261-282		67
176	Pyridine Ruthenium(III) complexes entrapped in liposomes with enhanced cytotoxic properties in PC-3 prostate cancer cells. 2019 , 51, 552-558		6
175	Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?. 2019 , 7, 31		60
174	A novel screening method for transition metal-based anticancer compounds using zebrafish embryo-larval assay and inductively coupled plasma-mass spectrometry analysis. 2019 , 39, 1173-1180		10
173	Reactivity and Transformation of Antimetastatic and Cytotoxic Rhodium(III)-Dimethyl Sulfoxide Complexes in Biological Fluids: An XAS Speciation Study. 2019 , 58, 4880-4893		6
172	Combinatorial Synthesis to Identify a Potent, Necrosis-Inducing Rhenium Anticancer Agent. 2019 , 58, 3895-3909		32
171	New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action. 2019 , 24, 297-310		5
170	Reactivity of CORM [RuII(CO)3Cl2{N3-(N1-methylbenzimidazole)}] with aminoacids. Synthesis, and analytical and structural study for the new binuclear cis-[RuI(CO)2(N3-MBI)(2-O,O-BAL)]2 sawhorse complex at solid state and in solution. 2019 , 1184, 479-486		
169	Coordination Behavior of N,N',N''-Trisubstituted Guanidine Ligands in Their Ru ^{II} Arene Complexes: Synthetic, DNA/Protein Binding, and Cytotoxic Studies. 2019 , 38, 753-770		30
168	The interaction between SBA-15 derivative loaded with PhSn(CH ₃)OH and human melanoma A375 cell line: uptake and stem phenotype loss. 2019 , 24, 223-234		15
167	Self-assembled ruthenium (II) metallacycles and metallacages with imidazole-based ligands and their in vitro anticancer activity. 2019 , 116, 4090-4098		24
166	Organoruthenium(II) complexes attenuate stress in <i>Caenorhabditis elegans</i> through regulating antioxidant machinery. <i>European Journal of Medicinal Chemistry</i> , 2019 , 168, 123-133	6.8	10
165	Photoinduced inhibition of DNA repair enzymes and the possible mechanism of photochemical transformations of the ruthenium nitrosyl complex [RuNO(Epic)(NO)OH]. <i>Metallomics</i> , 2019 , 11, 1999-2009	4.5	12
164	Validation and Applications of Protein-Ligand Docking Approaches Improved for Metalloligands with Multiple Vacant Sites. 2019 , 58, 294-306		25
163	Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?. 2019 , 119, 1058-1137		283
162	Half-sandwich ruthenium(II)-arene complexes: synthesis, spectroscopic studies, biological properties, and molecular modeling. 2019 , 72, 148-163		1

161	Nucleus-enriched Ruthenium Polypyridine Complex Acts as a Potent Inhibitor to Suppress Triple-negative Breast Cancer Metastasis. 2019 , 17, 21-30		9
160	Stimuli-Responsive Therapeutic Metalloodrugs. 2019 , 119, 1138-1192		257
159	The reduction of ruthenium(III) complexes with triazolopyrimidine ligands by ascorbic acid and mechanistic insight into their action in anticancer therapy. 2019 , 484, 305-310		10
158	Evaluation of (n-cymene) ruthenium diclofenac complex as anticancer chemotherapeutic agent: interaction with biomolecules, cytotoxicity assays. 2019 , 37, 3905-3913		6
157	Five novel palladium(II) complexes of 8-hydroxyquinoline and amino acids with hydrophobic side chains: synthesis, characterization, cytotoxicity, DNA- and BSA-interaction studies. 2020 , 38, 3059-3073		13
156	Quantum chemical investigation on the interaction of cysteine and DNA purine bases with aquated ruthenium(III) anticancer drug (ImH)[trans-RuCl ₄ (Im) ₂]. 2020 , 1172, 112664		2
155	Polymetallic Complexes for Applications as Photosensitisers in Anticancer Photodynamic Therapy. 2020 , 3, 1900139		14
154	Potent half-sandwich Ru(II) N ^N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities. <i>European Journal of Medicinal Chemistry</i> , 2020 , 207, 112763	6.8	6
153	Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metalloodrugs: A review. 2020 , 192, 114827		11
152	Fifty years of inorganic biochemistry: Developments, trends, highlights, impact and citations. <i>Journal of Inorganic Biochemistry</i> , 2020 , 212, 111230	4.2	3
151	Cytotoxic (-1,3,5-triaminocyclohexane)ruthenium(II)-diphosphine complexes; evidence for covalent binding intercalation with DNA. <i>Dalton Transactions</i> , 2020 , 49, 15219-15230	4.3	2
150	Ruthenium tetrazene complexes bearing glucose moieties on their periphery: Synthesis, characterization, and in vitro cytotoxicity. 2020 , 34, e5896		4
149	Mitochondria-Targeting Click-Derived Pyridinyltriazolylmethylquinoxaline-Based Y-Shaped Binuclear Luminescent Ruthenium(II) and Iridium(III) Complexes as Cancer Theranostic Agents. 2020 , 59, 17689-17711		8
148	Modification of multiwalled carbon nanotubes with a ruthenium drug candidate-indazolium[tetrachlorobis(1-indazole)ruthenate(III)] (KP1019). <i>Dalton Transactions</i> , 2020 , 49, 16791-16800	4.3	1
147	Binuclear 3,3',5,5'-tetramethyl-1H,H'-4,4'-bipyrazole Ruthenium(II) complexes: Synthesis, characterization and biological studies. 2020 , 513, 119902		5
146	Synthesis, characterization, HSA/DNA interactions and antitumor activity of new [Ru(η ⁶ -p-cymene)Cl(L)] complexes. <i>Journal of Inorganic Biochemistry</i> , 2020 , 213, 111256	4.2	10
145	Ruthenium(II)/(III) DMSO-Based Complexes of 2-Aminophenyl Benzimidazole with In Vitro and In Vivo Anticancer Activity. 2020 , 25,		14
144	Protein Metalation by Inorganic Anticancer Drugs. 2020 , 1-17		5

143	A mixed-valence diruthenium(II,III) complex endowed with high stability: from experimental evidence to theoretical interpretation. <i>Dalton Transactions</i> , 2020 , 49, 14520-14527	4.3	15
142	Hypoxia efficient and glutathione-resistant cytoselective ruthenium(II)-cymene-arylimidazophenanthroline complexes: biomolecular interaction and live cell imaging. <i>Dalton Transactions</i> , 2020 , 49, 12865-12878	4.3	9
141	Theoretical exploration of the photophysical properties of two-component Ru-porphyrin dyes as promising assemblies for a combined antitumor effect. <i>Dalton Transactions</i> , 2020 , 49, 12653-12661	4.3	2
140	Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy. 2020 , 15, 2121-2135		9
139	High Copper Complex Stability and Slow Reduction Kinetics as Key Parameters for Improved Activity, Paraptosis Induction, and Impact on Drug-Resistant Cells of Anticancer Thiosemicarbazones. 2020 , 33, 395-414		16
138	Synthesis, structure and anti-cancer activity of osmium complexes bearing η^6 -bound arene substituents and phosphane Co-Ligands: A review. <i>European Journal of Medicinal Chemistry</i> , 2020 , 201, 112483	6.8	11
137	Luminescent anticancer Ru(II)-arenebipyridine and phenanthroline complexes: Synthesis, characterization, DFT studies, biological interactions and cellular imaging application. <i>Journal of Inorganic Biochemistry</i> , 2020 , 208, 111099	4.2	8
136	Lighting up metallohelices: from DNA binders to chemotherapy and photodynamic therapy. 2020 , 56, 7537-7548		5
135	Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems. 2020 , 9,		9
134	Bifunctional ruthenium(II) polypyridyl complexes of curcumin as potential anticancer agents. <i>Dalton Transactions</i> , 2020 , 49, 9454-9463	4.3	8
133	Pharmacophore conjugation strategy for multi-targeting metal-based anticancer complexes. <i>Advances in Inorganic Chemistry</i> , 2020 , 257-285	2.1	0
132	Synthesis, Characterization, Cytotoxic Activity, and Metabolic Studies of Ruthenium(II) Polypyridyl Complexes Containing Flavonoid Ligands. 2020 , 59, 4424-4434		21
131	Ruthenium(III) complexes containing thiazole-based ligands that modulate amyloid- β aggregation. <i>Metallomics</i> , 2020 , 12, 491-503	4.5	7
130	Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2020 , 210, 111155	4.2	7
129	New Organometallic Ruthenium(II) Compounds Synergistically Show Cytotoxic, Antimetastatic and Antiangiogenic Activities for the Treatment of Metastatic Cancer. 2020 , 26, 15170-15182		8
128	Differences in Stability, Cytotoxicity, and Mechanism of Action of Ru(II) and Pt(II) Complexes of a Bidentate N,O Donor Ligand. 2020 , 59, 10262-10274		7
127	First Workshop on Metals in Medicine (2019): Translational Research in Medicinal Bioinorganic Chemistry. 2020 , 21, 2706-2707		
126	Ruthenium and iridium based mononuclear and multinuclear complexes: A Breakthrough of Next-Generation anticancer metallopharmaceuticals. 2020 , 512, 119858		8

125	Synthesis, characterization, antimicrobial and cytotoxic activity of novel half-sandwich Ru(II) arene complexes with benzoylthiourea derivatives. <i>Journal of Inorganic Biochemistry</i> , 2020 , 210, 111164	4.2	10
124	Unveiling the Role of Hydrogen Bonding and -Tensor in the Interaction of Ru-Bis-DMSO with Amino Acid Residue and Human Serum Albumin. 2020 , 124, 6459-6474		2
123	Ruthenium, rhodium and iridium complexes containing pyrimidine based thienyl pyrazoles: Synthesis and antibacterial studies. 2020 , 911, 121155		4
122	A Maltol-Containing Ruthenium Polypyridyl Complex as a Potential Anticancer Agent. 2020 , 26, 4997-5009		12
121	Synthesis, characterization, biological determination and catalytic evaluation of ruthenium(II) complexes bearing benzimidazole-based NHC ligands in transfer hydrogenation catalysis. <i>New Journal of Chemistry</i> , 2020 , 44, 5309-5323	3.6	12
120	Increasing the Cytotoxicity of Ru(II) Polypyridyl Complexes by Tuning the Electronic Structure of Dioxo Ligands. 2020 , 142, 6066-6084		23
119	Molecular Self-Assembly in a Family of Oxo-Bridged Dinuclear Ruthenium(IV) Systems. 2020 , 20, 2044-2056		7
118	150 years of the periodic table: New medicines and diagnostic agents. <i>Advances in Inorganic Chemistry</i> , 2020 , 75, 3-56	2.1	9
117	Multinuclear Ir-BODIPY complexes: Synthesis and binding studies. 2020 , 113, 107759		3
116	High-resolution crystal structures of a "half sandwich"-type Ru(II) coordination compound bound to hen egg-white lysozyme and proteinase K. 2020 , 25, 635-645		4
115	Synthesis and cytotoxic activities of organometallic Ru(II) diamine complexes. 2020 , 99, 103793		4
114	Synthesis and Structure of Arene Ru(II) N?O-Chelating Complexes: In Vitro Cytotoxicity and Cancer Cell Death Mechanism. 2020 , 39, 1366-1375		77
113	Proteomic analysis of the <i>S. cerevisiae</i> response to the anticancer ruthenium complex KP1019. <i>Metallomics</i> , 2020 , 12, 876-890	4.5	5
112	Effect of , Coordination and Ru Halide Bond in Enhancing Selective Toxicity of a Tyramine-Based Ru (-Cymene) Complex. 2020 , 59, 6581-6594		20
111	Ruthenium(II) Complex Containing a Redox-Active Semiquinonate Ligand as a Potential Chemotherapeutic Agent: From Synthesis to Studies. 2020 , 63, 5568-5584		9
110	Ruthenium(III) complexes with imidazole ligands that modulate the aggregation of the amyloid- β peptide via hydrophobic interactions. <i>Journal of Inorganic Biochemistry</i> , 2021 , 214, 111303	4.2	3
109	Synthesis of bis[benzyl- N? -hydrazinecarbodithioato- η^2 N? , S]nickel(II) complex as a novel lead molecule for cancer treatment. 2021 , 35,		2
108	A bis-indazolic ruthenium(II) complex: Reactivity and biological studies on cancer cells. 2021 , 516, 120125		0

107	A review on homo multinuclear anticancer Metallotherapeutics. 2021 , 517, 120184		2
106	Detection of Ru potential metallodrug in human urine by MALDI-TOF mass spectrometry: Validation and options to enhance the sensitivity. 2021 , 222, 121551		6
105	A Simple and Efficient Method for Quantitative Synthesis of Cu (II) Complexes in Presence of SiO ₂ : Structure Elucidation, DFT, Eukaryotic DNA, Antimicrobial and Potentiometric Studies. 2021 , 13, 993-1007		
104	Two mixed valence diruthenium(II,III) isomeric complexes show different anticancer properties. <i>Dalton Transactions</i> , 2021 , 50, 9643-9647	4-3	12
103	Ruthenium(ii)-arene complexes as anti-metastatic agents, and related techniques.. 2022 , 13, 22-38		2
102	Ru(ii), Ir(iii), Re(i) and Rh(iii) based complexes as next generation anticancer metallopharmaceuticals. <i>Dalton Transactions</i> , 2021 , 50, 11259-11290	4-3	4
101	Critical factors affecting the albumin binding of half-sandwich Ru(ii) and Rh(iii) complexes of 8-hydroxyquinolines and oligopyridines. <i>Dalton Transactions</i> , 2021 , 50, 11918-11930	4-3	1
100	The Medicinal Chemistry of Metal-Containing Anticancer drugs.		
99	Theoretical Determination of Influence of the Metallic State of Oxidation toward Cytotoxic Activity: Case of Ruthenium Complexes. 2021 , 09, 97-119		0
98	Nucleic acid-metal complex and its application in atomic-scale manufacturing. 2021 , 70, 028102-028102		
97	Ruthenium(II) p-cymene complexes of pyridine-2-carboxaldehyde and 2-amino benzothiazole-based ligands: cytoselective and in vitro live cell imaging agents. <i>New Journal of Chemistry</i> , 2021 , 45, 11317-11326		36
96	Ionic Ruthenium and Iron Based Complexes Bearing Silver Containing Anions as a Potent New Class of Anticancer Agents. 2021 , 934, 121659		2
95	In vitro evaluation of cytotoxicity and antimetastatic properties of novel arene ruthenium(II)-tetrazolato compounds on human cancer cell lines. 2021 , 35, e6187		2
94	Impact of the Metal Center and Leaving Group on the Anticancer Activity of Organometallic Complexes of Pyridine-2-carbothioamide. 2021 , 26,		2
93	Design, Synthesis and Pharmacological Evaluation of Three Novel Dehydroabietyl Piperazine Dithiocarbamate Ruthenium (II) Polypyridyl Complexes as Potential Antitumor Agents: DNA Damage, Cell Cycle Arrest and Apoptosis Induction. 2021 , 26,		4
92	Effect of an Imidazole-Containing Schiff Base of an Aromatic Sulfonamide on the Cytotoxic Efficacy of N,N-Coordinated Half-Sandwich Ruthenium(II) -Cymene Complexes. 2021 , 60, 4744-4754		9
91	Cytotoxicity of Tin(IV)-based compounds: A review. 2021 , 198, 115069		2
90	Synthesis of NNN Chiral Ruthenium Complexes and Their Cytotoxicity Studies. 2021 , 60, 7422-7432		4

89	DNA-Targeted Metallodrugs: An Untapped Source of Artificial Gene Editing Technology. 2021 , 22, 2184-2205	1
88	Photocytotoxic Activity of Ruthenium(II) Complexes with Phenanthroline-Hydrazone Ligands. 2021 , 26,	2
87	Half sandwiched Ruthenium(II) complexes: En Route towards the targeted delivery by Human Serum Albumin (HSA). 2021 , 937, 121732	5
86	Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time. 2021 , 60, 7974-7990	9
85	Imidazole/4,4'-azopyridine bridging binuclear Ru(II) complexes: design, synthesis, bimolecular interactions and cytotoxicity against HeLa cell line. 2021 , 18, 3313	
84	Binding of RuCp complexes with human apo-transferrin: fluorescence spectroscopy and molecular docking methods. 2021 , 34, 1029-1042	0
83	Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4. 2021 , 143, 9191-9205	9
82	Ruthenium Complexes as Promising Candidates against Lung Cancer. 2021 , 26,	8
81	Importance of Hydrogen Bonding: Structure-Activity Relationships of Ruthenium(III) Complexes with Pyridine-Based Ligands for Alzheimer's Disease Therapy. 2021 , 64, 10124-10138	3
80	A novel copper-catalyzed, hydrazine-free synthesis of N-1 unsubstituted 1H-indazoles using stable guanlylhydrazone salts as substrates. 2021 , 91, 132192	6
79	The palladacycle, BTC2, exhibits anti-breast cancer and breast cancer stem cell activity. 2021 , 190, 114598	5
78	Synthesis, Characterization, and Cytotoxicity of Morpholine-Containing Ruthenium(II) -Cymene Complexes. 2021 , 60, 12172-12185	1
77	Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment. <i>Pharmaceutics</i> , 2021 , 13,	6.4 6
76	The Development of Ru(II)-Based Photoactivated Chemotherapy Agents. 2021 , 26,	2
75	Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands. <i>Coordination Chemistry Reviews</i> , 2021 , 445, 213950	23.2 12
74	Conductometry of nano-sized zinc sulfate; synthesis and characterization of new hydrazone complexes: Conformational and in-vitro assay. 2021 , 340, 117167	11
73	Green synthesis for new Co(II), Ni(II), Cu(II) and Cd(II) hydrazone-based complexes; characterization, biological activity and electrical conductance of nano-sized copper sulphate. 2021 , 1244, 131238	11
72	Metal complexes with Picolinic acid frameworks and their antitumor activity. 2021 , 527, 120582	3

71	Water-soluble trithiolato-bridged dinuclear ruthenium(II) and osmium(II) arene complexes with bisphosphonate functionalized ligands as anticancer organometallics. <i>Journal of Inorganic Biochemistry</i> , 2021 , 225, 111618	4.2	
70	Synthesis, characterization, DNA binding and anticancer activities of the imidazolidine-functionalized (NHC)Ru(II) complexes. 2022 , 1247, 131350		3
69	Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: from molecular design to application. 2021 , 50, 4185-4219		159
68	Molecular pathways involved in cell death after chemically induced DNA damage. 2009 , 99, 209-30		4
67	Dose- and time-dependent tolerability and efficacy of organo-osmium complex FY26 and its tissue pharmacokinetics in hepatocarcinoma-bearing mice. <i>Metallomics</i> , 2021 , 13,	4-5	3
66	Anticancer activity of benzoxazole derivative (2015 onwards): a review. 2020 , 6,		11
65	Synthesis, Biological Activity and Medicinal Applications of Ruthenium Complexes Containing Carbohydrate Ligands. <i>Current Medicinal Chemistry</i> , 2019 , 26, 6412-6437	4-3	3
64	Structural, Conductometric and Antimicrobial Investigations of Ibuprofen Analgesic Drug Complexes with Certain Metal Ions. 2015 , 11, 773-785		2
63	Synthesis, Structure, and Peroxidase Activity of an Octahedral Ru(III) Complex with a Tripodal Tetraamine Ligand. 2011 , 32, 3904-3908		4
62	The binding properties of some novel ruthenium (III) complexes with human serum transferrin. 2011 , 27, 141-146		5
61	Synthesis, characterisation and biological activity of the ruthenium(II) complexes of the N-tetradentate (N-T), 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-diazahehexane (picenBz). <i>Journal of Inorganic Biochemistry</i> , 2022 , 226, 111629	4.2	
60	Chapter 10. Metal Ion-Nucleic Acid Interactions in Disease and Medicine. 2008 , 350-416		1
59	Metal-Based Indolobenzazepines and Indoloquinolines: From Moderate CDK Inhibitors to Potential Antitumor Drugs. 605-617		3
58	Metal Compounds as Kinase and Phosphatase Inhibitors in Drug Development: The Role of the Metal and Ligands. 301-330		
57	Co-ordination ability of Vinyl Imidazole(VIm), Imidazole(Im), Indazole(In), Ammonia(NH ₃) and Dimethyl sulphoxide (DMSO) Ligands in Ruthenium Complexes. 2020 , 36, 1134-1142		
56	Assessment of antiproliferative activity of new half-sandwich arene Ru (II) furylbenzhydrazone complexes. e6512		3
55	Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3 β /Fyn pathway. 2021 , 119, 105516		2
54	Photoactivable Ruthenium-Based Coordination Polymer Nanoparticles for Light-Induced Chemotherapy. 2021 , 11,		2

53	Metal complexes of NSAIDs as potent anti-tumor chemotherapeutics: Mechanistic insights into cytotoxic activity via multiple pathways primarily by inhibition of COX α and COX β enzymes. <i>Coordination Chemistry Reviews</i> , 2021 , 214316	23.2	3
52	Cytotoxic Ruthenium(II) Complexes Containing a Dangling Pyridine: Selectivity for Diseased Cells Mediated by pH-Dependent DNA Binding.. 2022 ,		0
51	Arene-Ruthenium(II) Complexes with Carbothiamidopyrazoles as a Potential Alternative for Antibiotic Resistance in Human.. 2022 , 27,		1
50	Mono- and Di-thiocarbonato complexes of ruthenium CpRu(CO) $_2$ SC(E)E?R (E, E?=O, S). 2022 , 534, 120824		
49	Synthesis a group of 5(6)-substitutedbenzimidazole Zn(II) and Co(II) complexes and investigation their cytotoxic and antimicrobial activities.		0
48	Mono-and Di-Thiocarbonato Complexes of Ruthenium CpRu(Co) <sub>2</sub>SC(E)E?R (E, E?= O,S).		
47	Metal complexes as chemotherapeutic agents. 2022 ,		
46	Protein targets for anticancer metal based drugs. 2022 ,		
45	Anticancer activity of ruthenium(II) plumbagin complexes with polypyridyl as ancillary ligands via inhibiting energy metabolism and GADD45A-mediated cell cycle arrest.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 236, 114312	6.8	2
44	A novel adenine-based diruthenium(III) complex: Synthesis, crystal structure, electrochemical properties and evaluation of the anticancer activity.. <i>Journal of Inorganic Biochemistry</i> , 2022 , 232, 111812	4.2	0
43	Ruthenium metalloterapeutics: novel approaches to combatting parasitic infections.. <i>Current Medicinal Chemistry</i> , 2022 ,	4.3	0
42	Construction of homo and heteronuclear Ru(II), Ir(III) and Re(I) complexes for target specific cancer therapy. <i>Coordination Chemistry Reviews</i> , 2022 , 460, 214462	23.2	2
41	Linking Chemistry and Biology through Course-Based Undergraduate Research on Anticancer Ruthenium Complexes. <i>Journal of Chemical Education</i> , 2022 , 99, 619-628	2.4	1
40	Synthesis, characterization, cytotoxicity and DNA/BSA binding of two amino acid palladium(II) complexes derived from alanine and valine. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021 , 1-26	1.4	0
39	Ru(III) Complexes with Lonidamine-Modified Ligands.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
38	Data_Sheet_1.doc. 2019 ,		
37	Left vs. Right: Exploring the Effects of Chiral Threading Intercalators using Optical Tweezers.. <i>Biophysical Journal</i> , 2022 ,	2.9	0
36	Syntheses, Structural and Serum Protein Protecting Activity of Ruthenium(II)-DMSO Complexes Containing Mercapto Ligand. <i>New Journal of Chemistry</i> ,	3.6	0

35	Synthesis, physicochemical characterization and antiproliferative activity of phosphino Ru(II) and Ir(III) complexes.. <i>Dalton Transactions</i> ,	4-3	
34	Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics. <i>Pharmaceutics</i> , 2022 , 14, 954	6.4	7
33	Factors that influence singlet oxygen formation vs. ligand substitution for light-activated ruthenium anticancer compounds.. <i>Current Opinion in Chemical Biology</i> , 2022 , 68, 102143	9-7	2
32	Hydrolytically stable organometallic ruthenium complexes with glucose-based phosphite ligands. <i>Russian Chemical Bulletin</i> , 2022 , 71, 962-966	1.7	1
31	Ruthenium complexes for photoactivated dual activity: Drug delivery and singlet oxygen generation. <i>Advances in Inorganic Chemistry</i> , 2022 ,	2.1	
30	The aqueous stability and interactions of organoruthenium compounds with serum proteins, cell culture medium and human serum. <i>Metallomics</i> ,	4-5	
29	Design and Anticancer Properties of New Water-Soluble Ruthenium Cyclopentadienyl Complexes. <i>Pharmaceutics</i> , 2022 , 15, 862	5-2	1
28	Bioengineered lipophilic Ru(III) complexes as potential anticancer agents. 2022 , 139, 213016		2
27	Combination of light and Ru(II) polypyridyl complexes: Recent advances in the development of new anticancer drugs. <i>Coordination Chemistry Reviews</i> , 2022 , 469, 214656	23-2	8
26	Ferromagnetic Coupling and Single-Ion Magnet Phenomenon in Mononuclear Ruthenium(III) Complexes Based on Guanine Nucleobase. 2022 , 8, 93		
25	Facets of ICP-MS and their potential in the medical sciences Part 1: fundamentals, stand-alone and hyphenated techniques.		0
24	Synthesis, photophysical properties and photo-induced cytotoxicity of novel tris(diazatriphenylene)ruthenium (II) complex. 2022 , 128, 106044		
23	Ruthenium(III) and (II) complexes containing pyridine moiety: Synthesis, crystal structure and in vitro biological evaluation. 2022 , 1270, 133929		0
22	A split β -lactamase sensor for the detection of DNA modification by cisplatin and ruthenium-based chemotherapeutic drugs. 2022 , 236, 111986		0
21	Phosphorescent metal complexes for biomedical applications. 2022 ,		0
20	ER Stress Response and Induction of Apoptosis in Malignant Pleural Mesothelioma: The Achilles Heel Targeted by the Anticancer Ruthenium Drug BOLD-100. 2022 , 14, 4126		1
19	Redox activity as a tool for bond activations and functionalizations. 2022 ,		0
18	Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy.		2

- 17 In vitro studies on the selective cytotoxic effect of luminescent Ru(II)-p-cymene complexes of imidazo-pyridine and imidazo quinoline ligands. ○
- 16 Conformation, hydration, and ligand exchange process of ruthenium nitrosyl complexes in aqueous solution: Free-energy calculations by a combination of molecular-orbital theories and different solvent models. ○
- 15 The Mechanism for Anticancer and Apoptosis-Inducing Properties of Cu(II) Complex with Quercetin and 1,10-Phenanthroline. **2022**, 7, ○
- 14 Biophysical insights into the binding capability of Cu(II) Schiff base complex with BSA protein and cytotoxicity studies against SiHa. **2022**, e11345 ○
- 13 Unprecedented cleavage of -N-N- bond of ligand and phenyl ring nitration during nitric oxide (NO) reactivity studies: new ruthenium nitrosyl complex and photoinduced liberation of NO. 1-11 ○
- 12 Arene Variation of Highly Cytotoxic Tridentate Naphthoquinone-Based Ruthenium(II) Complexes and In-Depth In Vitro Studies. **2022**, 14, 2466 1
- 11 In vitro cytotoxicity activity of copper complexes of imine and amine ligands: A combined experimental and computational study. **2022**, 146, 110190 ○
- 10 Synthesis and characterization of novel heterocyclic diazenyl pyridinone copper(II) complexes with antimicrobial, antioxidant, and anticancer properties. ○
- 9 Metallo-drug binding to serum albumin: Lessons from biophysical and structural studies. **2023**, 480, 215026 ○
- 8 Combined theoretical and experimental insights on DNA and BSA binding interactions of Cu(II) and Ni(II) complexes along with the DPPH method of antioxidant assay and cytotoxicity studies. **2023**, 13, 7632-7644 ○
- 7 Synthesis of Novel N-Heterocyclic Carbene-Ruthenium (II) Complexes, Precious Tools with Antibacterial, Anticancer and Antioxidant Properties. **2023**, 12, 693 ○
- 6 Ionic mononuclear [Fe] and heterodinuclear [Fe,Ru] bis(diphenylphosphino)alkane complexes: Synthesis, spectroscopy, DFT structures, cytotoxicity, and biomolecular interactions. **2023**, 242, 112156 ○
- 5 Half-Sandwich Ruthenium Arene Complexes Bearing Clinically Approved Drugs as Ligands: The Importance of Metal-Drug Synergism in Metallo-drug Design. **2023**, 20, 1453-1479 1
- 4 Synthesis, crystal structure and spectral studies of silver(I) cyclohexyldiphenylphosphine complexes: towards the biological evaluation on malignant and non-malignant cells. **2023**, 76, 45-60 ○
- 3 Promising anticancer agents based on 8-hydroxyquinoline hydrazone copper(II) complexes. 11, ○
- 2 Investigating the Interaction of an Anticancer Nucleolipidic Ru(III) Complex with Human Serum Proteins: A Spectroscopic Study. **2023**, 28, 2800 ○
- 1 Cytotoxicity and mechanism of action of metal complexes: An overview. **2023**, 153516 ○